



- (51) **International Patent Classification:**
A61K 31/404 (2006.01) *C07D 403/06* (2006.01)
- (21) **International Application Number:**
PCT/US2018/020668
- (22) **International Filing Date:**
02 March 2018 (02.03.2018)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/465,992 02 March 2017 (02.03.2017) US
- (71) **Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM [US/US];** 201 West 7th Street, Austin, Texas 78701 (US).
- (72) **Inventors: DALBY, Kevin N.;** 3 Warfield, Leander, Texas 78641 (US). **EDUPUGANTI, Ramakrishna;** 7333 Covered Bridge Drive, Austin, Texas 78736 (US). **TALIAFERRO, Juliana;** 906 Columbus St., Austin, Texas 78704 (US). **LEE, Juhyeon;** 2600 Lake Austin Blvd., #7102, Austin, Texas 78703 (US).
- (74) **Agent: PRATHER, Donald M. et al.;** Meunier Carlin & Curfman LLC, 999 Peachtree Street, NE, Suite 1300, Atlanta, Georgia 30309 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title:** INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE




FIG. 4

(57) **Abstract:** The present disclosure relates to indolinone compounds, compositions, and methods for the inhibition of maternal embryonic leucine zipper kinase (MELK). The present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE

CROSS REFERENCE TO RELATED APPLICATIONS

5 This application claims the benefit of U.S. Provisional Patent Application Serial No. 62/465,992 filed March 2, 2017, which is expressly incorporated herein by reference in its entirety.

FIELD

10 The present disclosure relates to indolinone compounds, compositions, and methods for the inhibition of maternal embryonic leucine zipper kinase (MELK). The present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).

BACKGROUND

15 Over the last two decades, protein kinases have represented a major field for drug discovery and development. However, one of these protein kinases, maternal embryonic leucine zipper kinase (MELK), has yet to be targeted by an FDA approved therapeutic.

20 Maternal embryonic leucine zipper kinase (MELK) is evolutionarily conserved in eukaryotes from nematodes to humans. In contrast to most members of the AMPK-RK family, which mediate cell survival under stressful metabolic conditions, MELK has been implicated in multiple cellular processes, including cell cycle checkpoint regulation, proliferation, apoptosis, and RNA processing. MELK is expressed in the early stages of murine embryonic development, but MELK knockout mice develop normally with no obvious pathologic phenotype, suggesting that MELK's developmentally-related functions may be redundant. Yet despite its apparent
25 dispensable nature in differentiated adult cells, evidence has implicated MELK's importance in proliferating progenitor populations, including multipotent neural progenitors, myoblasts, and mammary progenitors. Interestingly, MELK inhibition does not affect survival in normal neural stem cells, but siRNA-mediated MELK knockdown induces apoptosis selectively in glioma stem cells. Such data reinforces the redundancy of MELK function in noncancerous cells, but also
30 implicates the existence of an exploitable target in certain cancer stem cell populations.

 In addition to its putative role in cancer stem cells, upregulated MELK mRNA and protein levels have been observed in a wide array of cancer cell types and clinical tumor samples. Of particular note is the fact that MELK expression correlates with poor prognosis in the most aggressive subsets of disease, including glioblastoma multiforme (GBM) and triple negative breast
35 cancer (TNBC). Factors contributing to poor outlook for TNBC patients in part stems from the


cancer's ability not only to proliferate quickly, but also its propensity to spread and recur in distant organs. From a molecular biology perspective, mounting evidence continues to implicate MELK in direct and transcriptional regulation of cell division in the context of malignancy. Furthermore, MELK has also been preliminarily linked to metastasis through its involvement with TGF- β driven epithelial-to-mesenchymal transition (EMT). The cancer-specific expression pattern, combined with the clinical and biological data have therefore justifiably fostered strong interest in MELK as a clinical target.

The compounds, compositions, and methods disclosed herein address these and other needs.

SUMMARY

Disclosed herein are indolinone compounds, compositions, and methods for the potent and selective inhibition of maternal embryonic leucine zipper (MELK) kinase. In some embodiments, the present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).

In one aspect, disclosed herein is a compound of Formula I:



Formula I


wherein:

R¹ is hydrogen;

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino; and

R³ is selected from aryl or heteroaryl;
or a pharmaceutically acceptable salt thereof.

In one aspect, disclosed herein is a compound of Formula II:



5

Formula II


wherein:

R¹ is hydrogen; and

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino,
aminoacyl, or amino;

10 or a pharmaceutically acceptable salt thereof.

In one aspect, disclosed herein is a compound of Formula III:




Formula III

wherein:

- 5 R¹ is hydrogen;
 R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
 each R⁴ is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl, alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro,
 10 heterocycloalkyl, heterocycloalkylalkyl, or NR⁵R⁶; or
 two R⁴ come together to form a carbocyclic ring or a heterocyclic ring;
 R⁵ and R⁶ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester; and
 x is selected from 1 or 2;
 15 or a pharmaceutically acceptable salt thereof.

In one aspect, disclosed herein is a compound of Formula IV:




Formula IV


wherein:

- 5 R^1 is hydrogen;
 R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
each R^4 is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro,
10 heterocycloalkyl, heterocycloalkylalkyl, or NR^5R^6 ; or
two R^4 come together to form a carbocyclic ring or a heterocyclic ring;
 R^5 and R^6 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl,
or ester;
 R^7 is selected from NR^8R^9 , alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl;
15 R^8 and R^9 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl,
heterocycloalkylalkyl, or acyl; and
x is selected from 1 or 2;
or a pharmaceutically acceptable salt thereof.


In one embodiment, the compound is



In another embodiment, the compound is




In one aspect, provided herein is a method for the treatment of a cancer, comprising:
administering an effective amount of a compound of Formula I to a host in need thereof:



Formula I

- 5 wherein:
- R¹ is hydrogen;
- R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino,
aminoacyl, or amino; and
- R³ is selected from aryl or heteroaryl;
- 10 or a pharmaceutically acceptable salt thereof.

In another aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound of Formula II to a host in need thereof:



Formula II


5 wherein:

R¹ is hydrogen; and

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino;

or a pharmaceutically acceptable salt thereof.


In one aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound of Formula III to a host in need thereof:



Formula III

- 5 wherein:
- R^1 is hydrogen;
- R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
- each R^4 is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
- 10 alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro, heterocycloalkyl, heterocycloalkylalkyl, or NR^5R^6 ; or
- two R^4 come together to form a carbocyclic ring or a heterocyclic ring;
- R^5 and R^6 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester; and
- 15 x is selected from 1 or 2;
- or a pharmaceutically acceptable salt thereof.

In one aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound of Formula IV to a host in need thereof:



Formula IV

- 5 wherein:
- R¹ is hydrogen;
- R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
- each R⁴ is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
- 10 alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro, heterocycloalkyl, heterocycloalkylalkyl, or NR⁵R⁶; or
- two R⁴ come together to form a carbocyclic ring or a heterocyclic ring;
- R⁵ and R⁶ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester;
- 15 R⁷ is selected from NR⁸R⁹, alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl;
- R⁸ and R⁹ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, heterocycloalkylalkyl, or acyl; and
- x is selected from 1 or 2;
- or a pharmaceutically acceptable salt thereof.

20

In one embodiment, the cancer is selected from triple negative breast cancer or glioblastoma multiforme. In one embodiment, the cancer is triple negative breast cancer. In one embodiment, the cancer is glioblastoma multiforme.

In one embodiment, a compound of Formula I, II, III, or IV is administered in combination with an additional chemotherapeutic agent.

BRIEF DESCRIPTION OF THE DRAWINGS

5 The accompanying figures, which are incorporated in and constitute a part of this specification, illustrate several aspects described below.

FIG. 1 shows the top 3 screening hits for inhibition of maternal embryonic leucine zipper kinase (MELK), with key predicted hydrogen-bonding interactions with MELK binding site and their IC_{50} 's: A) Nintedanib; B) S1529 (Hesperadin); and C) CC-401.

10 FIG. 2 shows the molecular interactions between nintedanib and Cpd2 with MELK. Molecular modeling studies were performed using Gold 5.1 (Cambridge Crystallographic Data Center). A) Docking of nintedanib ($IC_{50} \sim 43$ nM) into the ATP-binding site of the MELK conformation PDB 4BKY. B) Crystal structure of a benzodipyrzazole inhibitor (Cpd2) in complex with the MELK catalytic domain (PDB: 4BKZ).

15 FIG. 3 shows the top-down view of the ATP binding pocket of MELK (PDB: 4BKY) and predicted binding poses of compounds 15 (6-CO₂Me, A) and 17 (5-CO₂Me, B). A) Compound 15 forms hydrogen bonds with C89, E87, and K40 of the ATP binding pocket. 6th position substitution sterically prevents 15 from achieving optimal complementarity with the curvature of the binding site. B) 5th position methyl ester substitution in 17 forms the same hydrogen bonds, but allows deeper penetration of the compound into the binding site, shortening hydrogen bond lengths between MELK and the compound by up to an angstrom in some cases. Measurements were generated using Pymol software. H-bonds are shown as dashed black lines. ATP binding pocket is shaded in light purple. Ribbon backbones of residues 13–19 and 23–27 are excluded for clarity.

25 FIG. 4 shows inhibitor 17 suppresses cell proliferation of triple negative breast cancer (TNBC) cells *in vitro*. Inhibitor 17 was more effective than inhibitor 19 at suppressing cell proliferation, and cells expressing high levels of MELK were more sensitive to inhibitor 17 than cells expressing low levels of MELK. Cells were seeded in 96-well plates and the next day treated with inhibitors at the indicated concentrations. Seventy-two hours later, cell viability was determined using the CellTiter-Blue Cell Viability Assay for the following cell lines: A) HCC70; B) BT549; C) SUM159; and D) MCF-10A cell lines. E) MELK expression levels are shown for HCC70, BT549, and SUM159 cell lines. Tubulin is shown as the loading control.

35 FIG. 5 shows time course and IC_{50} plots for the three most potent inhibitors, compounds 16, 17, and 21. (a) Time course for inhibition at different concentrations for compound 16. (b) IC_{50} plot showing fractional activity vs. inhibitor concentration for compound 16. (c) Time course for

inhibition at different concentrations for compound 17. (d) IC₅₀ plot showing fractional activity vs. inhibitor concentration for compound 17. (e) Time course for inhibition at different concentrations for compound 21. (f) IC₅₀ plot showing fractional activity vs. inhibitor concentration for compound 21. Rates derived for compounds 16 and 21 represent the average for three independent experiments, whereas those for compound 17 are the average for 4 separate experiments. K_i values were fit directly in Prism[®] using experimentally determined K_M^{ATP} of $6 \pm 1.5 \mu\text{M}$ (two independent replicates) and an ATP concentration of $40 \mu\text{M}$.

FIG. 6 shows the X-ray structure for the 5-CO₂Me analog (compound 17).

10 DETAILED DESCRIPTION

Disclosed herein are indolinone compounds, compositions, and methods for the potent and selective inhibition of maternal embryonic leucine zipper (MELK) kinase. In some embodiments, the present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).

15 Reference will now be made in detail to the embodiments of the invention, examples of which are illustrated in the drawings and the examples. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. The following definitions are provided for the full understanding of terms used in this specification.

Terminology

As used in the specification and claims, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

As used herein, the terms “may,” “optionally,” and “may optionally” are used interchangeably and are meant to include cases in which the condition occurs as well as cases in which the condition does not occur. Thus, for example, the statement that a formulation “may include an excipient” is meant to include cases in which the formulation includes an excipient as well as cases in which the formulation does not include an excipient.

As used here, the terms “beneficial agent” and “active agent” are used interchangeably herein to refer to a chemical compound or composition that has a beneficial biological effect. Beneficial biological effects include both therapeutic effects, i.e., treatment of a disorder or other undesirable physiological condition, and prophylactic effects, i.e., prevention of a disorder or other

undesirable physiological condition. The terms also encompass pharmaceutically acceptable, pharmacologically active derivatives of beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, and the like. When the terms “beneficial agent” or “active agent” are used, then, or when a particular agent is specifically identified, it is to be understood that the term includes the agent per se as well as pharmaceutically acceptable, pharmacologically active salts, esters, amides, prodrugs, conjugates, active metabolites, isomers, fragments, analogs, etc.

As used herein, the terms “treating” or “treatment” of a subject includes the administration of a drug to a subject with the purpose of preventing, curing, healing, alleviating, relieving, altering, remedying, ameliorating, improving, stabilizing or affecting a disease or disorder, or a symptom of a disease or disorder. The terms “treating” and “treatment” can also refer to reduction in severity and/or frequency of symptoms, elimination of symptoms and/or underlying cause, prevention of the occurrence of symptoms and/or their underlying cause, and improvement or remediation of damage.

As used herein, the term “preventing” a disorder or unwanted physiological event in a subject refers specifically to the prevention of the occurrence of symptoms and/or their underlying cause, wherein the subject may or may not exhibit heightened susceptibility to the disorder or event.

By the term “effective amount” of a therapeutic agent is meant a nontoxic but sufficient amount of a beneficial agent to provide the desired effect. The amount of beneficial agent that is “effective” will vary from subject to subject, depending on the age and general condition of the subject, the particular beneficial agent or agents, and the like. Thus, it is not always possible to specify an exact “effective amount.” However, an appropriate “effective” amount in any subject case may be determined by one of ordinary skill in the art using routine experimentation. Also, as used herein, and unless specifically stated otherwise, an “effective amount” of a beneficial can also refer to an amount covering both therapeutically effective amounts and prophylactically effective amounts.

An “effective amount” of a drug necessary to achieve a therapeutic effect may vary according to factors such as the age, sex, and weight of the subject. Dosage regimens can be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

As used herein, a “therapeutically effective amount” of a therapeutic agent refers to an amount that is effective to achieve a desired therapeutic result, and a “prophylactically effective amount” of a therapeutic agent refers to an amount that is effective to prevent an unwanted

physiological condition. Therapeutically effective and prophylactically effective amounts of a given therapeutic agent will typically vary with respect to factors such as the type and severity of the disorder or disease being treated and the age, gender, and weight of the subject.

The term “therapeutically effective amount” can also refer to an amount of a therapeutic agent, or a rate of delivery of a therapeutic agent (e.g., amount over time), effective to facilitate a desired therapeutic effect. The precise desired therapeutic effect will vary according to the condition to be treated, the tolerance of the subject, the drug and/or drug formulation to be administered (e.g., the potency of the therapeutic agent (drug), the concentration of drug in the formulation, and the like), and a variety of other factors that are appreciated by those of ordinary skill in the art.

As used herein, the term “pharmaceutically acceptable” component can refer to a component that is not biologically or otherwise undesirable, i.e., the component may be incorporated into a pharmaceutical formulation of the invention and administered to a subject as described herein without causing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained. When the term “pharmaceutically acceptable” is used to refer to an excipient, it is generally implied that the component has met the required standards of toxicological and manufacturing testing or that it is included on the Inactive Ingredient Guide prepared by the U.S. Food and Drug Administration.

Also, as used herein, the term “pharmacologically active” (or simply “active”), as in a “pharmacologically active” derivative or analog, can refer to a derivative or analog (e.g., a salt, ester, amide, conjugate, metabolite, isomer, fragment, etc.) having the same type of pharmacological activity as the parent compound and approximately equivalent in degree.

As used herein, the term “subject” or “host” can refer to living organisms such as mammals, including, but not limited to humans, livestock, dogs, cats, and other mammals. Administration of the therapeutic agents can be carried out at dosages and for periods of time effective for treatment of a subject. In some embodiments, the subject is a human.

Chemical Terminology

As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, and aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described below. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this disclosure, the heteroatoms, such as nitrogen, can have

hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This disclosure is not intended to be limited in any manner by the permissible substituents of organic compounds. Also, the terms “substitution” or “substituted with” include the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, *e.g.*, a compound that does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc.

“Z¹,” “Z²,” “Z³,” and “Z⁴” are used herein as generic symbols to represent various specific substituents. These symbols can be any substituent, not limited to those disclosed herein, and when they are defined to be certain substituents in one instance, they can, in another instance, be defined as some other substituents.

The term “aliphatic” as used herein refers to a non-aromatic hydrocarbon group and includes branched and unbranched, alkyl, alkenyl, or alkynyl groups.

The term “alkyl” as used herein is a branched or unbranched saturated hydrocarbon group. In some embodiments, the alkyl comprises 1 to 10 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and the like. The alkyl group can also be substituted or unsubstituted. The alkyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.

Throughout the specification “alkyl” is generally used to refer to both unsubstituted alkyl groups and substituted alkyl groups; however, substituted alkyl groups are also specifically referred to herein by identifying the specific substituent(s) on the alkyl group. For example, the term “halogenated alkyl” specifically refers to an alkyl group that is substituted with one or more halide, *e.g.*, fluorine, chlorine, bromine, or iodine. The term “alkoxyalkyl” specifically refers to an alkyl group that is substituted with one or more alkoxy groups, as described below. The term “alkylamino” specifically refers to an alkyl group that is substituted with one or more amino groups, as described below, and the like. When “alkyl” is used in one instance and a specific term such as “alkylalcohol” is used in another, it is not meant to imply that the term “alkyl” does not also refer to specific terms such as “alkylalcohol” and the like. This practice is also used for other groups described herein. That is, while a term such as “cycloalkyl” refers to both unsubstituted and substituted cycloalkyl moieties, the substituted moieties can, in addition, be specifically identified herein; for example, a particular substituted cycloalkyl can be referred to as, *e.g.*, an “alkylcycloalkyl.” Similarly, a substituted alkoxy can be specifically referred to as, *e.g.*, a “halogenated alkoxy,” a particular substituted alkenyl can be, *e.g.*, an “alkenylalcohol,” and the

like. Again, the practice of using a general term, such as “cycloalkyl,” and a specific term, such as “alkylcycloalkyl,” is not meant to imply that the general term does not also include the specific term.

The term “alkoxy” as used herein is an alkyl group bound through a single, terminal ether linkage; that is, an “alkoxy” group can be defined as —OZ^1 where Z^1 is alkyl as defined above.

The term “alkenyl” as used herein is a hydrocarbon group of from 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon double bond. Asymmetric structures such as $(\text{Z}^1\text{Z}^2)\text{C}=\text{C}(\text{Z}^3\text{Z}^4)$ are intended to include both the *E* and *Z* isomers. This can be presumed in structural formulae herein wherein an asymmetric alkene is present, or it can be explicitly indicated by the bond symbol $\text{C}=\text{C}$. The alkenyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.

The term “alkynyl” as used herein is a hydrocarbon group of 2 to 24 carbon atoms with a structural formula containing at least one carbon-carbon triple bond. The alkynyl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol, as described below.

The term “aryl” as used herein is a group that contains any carbon-based aromatic group including, but not limited to, benzene, naphthalene, phenyl, biphenyl, phenoxybenzene, and the like. The term “heteroaryl” is defined as a group that contains an aromatic group that has at least one heteroatom incorporated within the ring of the aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus. The term “non-heteroaryl,” which is included in the term “aryl,” defines a group that contains an aromatic group that does not contain a heteroatom. The aryl or heteroaryl group can be substituted or unsubstituted. The aryl or heteroaryl group can be substituted with one or more groups including, but not limited to, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein. The term “biaryl” is a specific type of aryl group and is included in the definition of aryl. Biaryl refers to two aryl groups that are bound together *via* a fused ring structure, as in naphthalene, or are attached *via* one or more carbon-carbon bonds, as in biphenyl.

The term “cycloalkyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. The term “heterocycloalkyl” is a cycloalkyl

group as defined above where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkyl group and heterocycloalkyl group can be substituted or unsubstituted. The cycloalkyl group and heterocycloalkyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.

The term “cycloalkenyl” as used herein is a non-aromatic carbon-based ring composed of at least three carbon atoms and containing at least one double bond, *i.e.*, C=C. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, and the like. The term “heterocycloalkenyl” is a type of cycloalkenyl group as defined above, and is included within the meaning of the term “cycloalkenyl,” where at least one of the carbon atoms of the ring is substituted with a heteroatom such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. The cycloalkenyl group and heterocycloalkenyl group can be substituted or unsubstituted. The cycloalkenyl group and heterocycloalkenyl group can be substituted with one or more groups including, but not limited to, alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, sulfonyl, sulfone, sulfoxide, or thiol as described herein.

The term “cyclic group” is used herein to refer to either aryl groups, non-aryl groups (*i.e.*, cycloalkyl, heterocycloalkyl, cycloalkenyl, and heterocycloalkenyl groups), or both. Cyclic groups have one or more ring systems that can be substituted or unsubstituted. A cyclic group can contain one or more aryl groups, one or more non-aryl groups, or one or more aryl groups and one or more non-aryl groups.

The term “aldehyde” as used herein is represented by the formula —C(O)H. Throughout this specification “C(O)” or “CO” is a short hand notation for C=O.

The terms “amine” or “amino” as used herein are represented by the formula —NZ¹Z², where Z¹ and Z² can each be substitution group as described herein, such as hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. The term “aminoacyl” specifically refers to an amino group that is substituted with one or more acyl groups, as described below.

The term “carboxylic acid” as used herein is represented by the formula —C(O)OH. A “carboxylate” or “carboxyl” group as used herein is represented by the formula —C(O)O⁻.

The term "ester" as used herein is represented by the formula —OC(O)Z^1 or —C(O)OZ^1 , where Z^1 can be an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. The term "alkylester" indicates an alkyl group as defined herein covalently bound to the group it substitutes by an ester linkage. The ester linkage may be in either orientation, e.g., a group of the formula —O(C=O)alkyl or a group of the formula —(C=O)Oalkyl .

The term "ether" as used herein is represented by the formula $Z^1\text{OZ}^2$, where Z^1 and Z^2 can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

The term "ketone" as used herein is represented by the formula $Z^1\text{C(O)Z}^2$, where Z^1 and Z^2 can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

The term "acyl" refers to a group of the formula —C(O)Z^1 , wherein Z^1 can be an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above. For example, the term "C₂₋₇ acyl" as used herein, either alone or in combination with another substituent, means a C₁₋₆ alkyl group linked through a carbonyl group such as —C(O)—C_{1-6} alkyl.

The term "amide" or "carboxamide" refers to a group of the formula $\text{—C(O)NZ}^1\text{Z}^2$ where Z^1 and Z^2 can be, independently, an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above; or together with the nitrogen to which they are bonded, Z^1 and Z^2 can form a heterocyclic ring.

The term "halide" or "halogen" or "halo" as used herein refers to the fluorine, chlorine, bromine, and iodine.

The term "hydroxyl" or "hydroxy" as used herein is represented by the formula —OH .

The term "nitro" as used herein is represented by the formula —NO_2 .

The term "silyl" as used herein is represented by the formula $\text{—SiZ}^1\text{Z}^2\text{Z}^3$, where Z^1 , Z^2 , and Z^3 can be, independently, hydrogen, alkyl, halogenated alkyl, alkoxy, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

The term "sulfonyl" is used herein to refer to the sulfo-oxo group represented by the formula $\text{—S(O)}_2\text{Z}^1$, where Z^1 can be hydrogen, an alkyl, halogenated alkyl, alkenyl, alkynyl, acyl, aryl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, or heterocycloalkenyl group described above.

The term “sulfonylamino” or “sulfonamide” as used herein is represented by the formula —S(O)₂NH—.

The term “thiol” as used herein is represented by the formula —SH.

The term “thio” as used herein is represented by the formula —S—.


5 “R¹,” “R²,” “R³,” “Rⁿ,” etc., where n is some integer, as used herein can, independently, possess one or more of the groups listed above. For example, if R¹ is a straight chain alkyl group, one of the hydrogen atoms of the alkyl group can optionally be substituted with a hydroxyl group, an alkoxy group, an amine group, an alkyl group, a halide, and the like. Depending upon the groups that are selected, a first group can be incorporated within second group or, alternatively,
10 the first group can be pendant (*i.e.*, attached) to the second group. For example, with the phrase “an alkyl group comprising an amino group,” the amino group can be incorporated within the backbone of the alkyl group. Alternatively, the amino group can be attached to the backbone of the alkyl group. The nature of the group(s) that is (are) selected will determine if the first group is embedded or attached to the second group.

15 Unless stated to the contrary, a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, *e.g.*, each enantiomer, diastereomer, and meso compound, and a mixture of isomers, such as a racemic or scalemic mixture.

20 Reference will now be made in detail to specific aspects of the disclosed materials, compounds, compositions, and methods, examples of which are illustrated in the accompanying Examples and Figures.

Compounds

In one aspect, disclosed herein is a compound of Formula I:



Formula I

5 wherein:


R¹ is hydrogen;

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino; and

R³ is selected from aryl or heteroaryl;

10 or a pharmaceutically acceptable salt thereof.

In another aspect, disclosed herein is a compound of Formula II:




Formula II

wherein:

- 5 R¹ is hydrogen; and
R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino;
or a pharmaceutically acceptable salt thereof.

In one aspect, disclosed herein is a compound of Formula III:




Formula III

wherein:

- 5 R¹ is hydrogen;
 R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
 each R⁴ is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl, alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro,
 10 heterocycloalkyl, heterocycloalkylalkyl, or NR⁵R⁶; or
 two R⁴ come together to form a carbocyclic ring or a heterocyclic ring;
 R⁵ and R⁶ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester; and
 x is selected from 1 or 2;
 15 or a pharmaceutically acceptable salt thereof.

In one aspect, disclosed herein is a compound of Formula IV:



Formula IV

wherein:

- 5 R^1 is hydrogen;
 R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
 each R^4 is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
 alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro,
 10 heterocycloalkyl, heterocycloalkylalkyl, or NR^5R^6 ; or
 two R^4 come together to form a carbocyclic ring or a heterocyclic ring;
 R^5 and R^6 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl,
 or ester;
 R^7 is selected from NR^8R^9 , alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl;
 15 R^8 and R^9 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl,
 heterocycloalkylalkyl, or acyl; and
 x is selected from 1 or 2;
 or a pharmaceutically acceptable salt thereof.

- 20 In one embodiment, R^2 is unsubstituted. In one embodiment, R^2 is substituted. In one embodiment, R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino. In one embodiment, R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl. In one

embodiment, R^2 is ester. In one embodiment, R^2 is alkylester. In one embodiment, R^2 is methyl ester. In one embodiment, R^2 is carboxylic acid. In one embodiment, R^2 is ester. In one embodiment, R^2 is amide. In one embodiment, R^2 is acyl. In one embodiment, R^2 is sulfonamide. In one embodiment, R^2 is alkylamino. In one embodiment, R^2 is aminoacyl. In one embodiment, R^2 is amino. In one embodiment, R^2 is nitro. In one embodiment, R^2 is aryl. In one embodiment, R^2 is heteroaryl.

In one embodiment, R^2 is alkoxy. In one embodiment, R^2 is substituted alkoxy. In one embodiment, R^2 is alkoxy, wherein the alkoxy is substituted with alkyl, aryl, alkylaryl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, or heterocycloalkylalkyl.

In one embodiment, R^3 is unsubstituted. In one embodiment, R^3 is substituted. In one embodiment, R^3 is selected from aryl or heteroaryl. In one embodiment, R^3 is selected from phenyl, benzyl, pyridine, or furan. In one embodiment, R^3 is unsubstituted aryl. In one embodiment, R^3 is phenyl. In one embodiment, R^3 is substituted aryl. In one embodiment, R^3 is substituted aryl, wherein the substituted aryl is an aryl group substituted with alkyl, amino, alkylamino, amide, aminoacyl, hydroxy, alkoxy, aryloxy, carboxylic acid, or ester, or a combination thereof. In one embodiment, R^3 is pyridine. In one embodiment, R^3 is a pyridine derivative. In one embodiment, R^3 is a substituted pyridine. In one embodiment, R^3 is furan.

In one embodiment, R^3 is unsubstituted heteroaryl. In one embodiment, R^3 is substituted heteroaryl. In one embodiment, R^3 is substituted heteroaryl, wherein the substituted heteroaryl is a heteroaryl group substituted with alkyl, amino, alkylamino, amide, aminoacyl, hydroxy, alkoxy, aryloxy, carboxylic acid, or ester, or a combination thereof.

In some embodiments, each R^4 is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl, alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro, heterocycloalkyl, heterocycloalkylalkyl, or NR^5R^6 . In some embodiments, two R^4 come together to form a carbocyclic ring or a heterocyclic ring.

In some embodiments, two R^4 come together to form an unsubstituted or substituted carbocyclic ring; or an unsubstituted or substituted heterocyclic ring.

In some embodiments, R^4 is hydrogen. In some embodiments, R^4 is alkyl. In some embodiments, R^4 is carboxylic acid. In some embodiments, R^4 is ester. In some embodiments, R^4 is amide. In some embodiments, R^4 is acyl. In some embodiments, R^4 is alkoxy. In some embodiments, R^4 is hydroxyl. In some embodiments, R^4 is hydroxyalkyl. In some embodiments, R^4 is sulfonamide. In some embodiments, R^4 is alkylamino. In some embodiments, R^4 is aminoacyl. In some embodiments, R^4 is amino. In some embodiments, R^4 is nitro. In some embodiments, R^4 is heterocycloalkyl. In some embodiments, R^4 is heterocycloalkylalkyl. In some embodiments, R^4 is NR^5R^6 .


In some embodiments, R^5 and R^6 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester. In some embodiments, R^5 is hydrogen. In some embodiments, R^5 is alkyl. In some embodiments, R^5 is alkylamino. In some embodiments, R^5 is heterocycloalkyl. In some embodiments, R^5 is acyl. In some embodiments, R^5 is ester. In some
5 embodiments, R^6 is hydrogen. In some embodiments, R^6 is alkyl. In some embodiments, R^6 is alkylamino. In some embodiments, R^6 is heterocycloalkyl. In some embodiments, R^6 is acyl. In some embodiments, R^6 is ester.

In some embodiments, R^7 is selected from NR^8R^9 , alkyl, alkylamino, or heterocycloalkyl. In some embodiments, R^7 is NR^8R^9 . In some embodiments, R^7 is alkyl. In some embodiments, R^7
10 is alkylamino. In some embodiments, R^7 is heterocycloalkyl.


In some embodiments, R^8 and R^9 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, heterocycloalkylalkyl, or acyl. In some embodiments, R^8 is hydrogen. In some embodiments, R^8 is alkyl. In some embodiments, R^8 is alkylamino. In some
15 embodiments, R^8 is heterocycloalkyl. In some embodiments, R^8 is heterocycloalkylalkyl. In some embodiments, R^8 is acyl. In some embodiments, R^8 is substituted acyl. In some embodiments, R^8 is acyl, wherein the acyl is substituted with hydrogen, alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl. In some
20 embodiments, R^9 is hydrogen. In some embodiments, R^9 is alkyl. In some embodiments, R^9 is alkylamino. In some embodiments, R^9 is heterocycloalkyl. In some embodiments, R^9 is heterocycloalkylalkyl. In some embodiments, R^9 is acyl. In some
embodiments, R^9 is substituted acyl. In some embodiments, R^9 is acyl, wherein the acyl is substituted with hydrogen, alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl.

In some embodiments, x is selected from 1 or 2. In some embodiments, x is 2. In some
embodiments, x is 1.

In one embodiment, the compound is



In another embodiment, the compound is



In some embodiments, the compound of Formula I, II, III, or IV is selected from the
5 compounds listed in Table 1.

Table 1. Non-limiting examples of compounds of Formula I, II, III, or IV

Compound	Structure
17	
18	
19	

Compound	Structure
21	
24	
25	

In some embodiments, the compound of Formula I, II, III, or IV is selected from the compounds listed in Table 2.

Table 2. Additional non-limiting examples of compounds of Formula I, II, III, or IV

Table 2 Structure No.	Structure
91	





Table 2 Structure No.	Structure
92	
93	
94	
95	





Table 2 Structure No.	Structure
96	
97	
98	
100	














Table 2 Structure No.	Structure
102	
103	
104	
105	

Table 2 Structure No.	Structure
106	
107	
108	


In some embodiments, the compound of Formula I, II, III, or IV is selected from the compounds listed in Table 3.

5 Table 3. Additional non-limiting examples of compounds of Formula I, II, III, or IV


Table 3 Structure No.	Structure
109	
110	
111	
112	
113	




120




121




122




123




124




125




126




127




128




129




130




131



132




In some embodiments, the compound is:



5 Methods

In one aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound of Formula I to a host in need thereof:



Formula I

10 wherein:


R¹ is hydrogen;

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino; and

R³ is selected from aryl or heteroaryl;

15 or a pharmaceutically acceptable salt thereof.


In one aspect, provided herein is a method for the treatment of a cancer, comprising:
administering an effective amount of a compound of Formula III to a host in need thereof:



Formula III

- 5 wherein:
- R^1 is hydrogen;
- R^2 is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
- each R^4 is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
- 10 alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro, heterocycloalkyl, heterocycloalkylalkyl, or NR^5R^6 ; or
- two R^4 come together to form a carbocyclic ring or a heterocyclic ring;
- R^5 and R^6 are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester; and
- 15 x is selected from 1 or 2;
- or a pharmaceutically acceptable salt thereof.

In one aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound of Formula IV to a host in need thereof:



Formula IV

- 5 wherein:
- R¹ is hydrogen;
- R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, amino, nitro, aryl, or heteroaryl;
- each R⁴ is independently selected from hydrogen, alkyl, carboxylic acid, ester, amide, acyl,
- 10 alkoxy, hydroxyl, hydroxyalkyl, sulfonamide, alkylamino, aminoacyl, amino, nitro, heterocycloalkyl, heterocycloalkylalkyl, or NR⁵R⁶; or
- two R⁴ come together to form a carbocyclic ring or a heterocyclic ring;
- R⁵ and R⁶ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, acyl, or ester;
- 15 R⁷ is selected from NR⁸R⁹, alkyl, alkylamino, heterocycloalkyl, or heterocycloalkylalkyl;
- R⁸ and R⁹ are independently selected from hydrogen, alkyl, alkylamino, heterocycloalkyl, heterocycloalkylalkyl, or acyl; and
- x is selected from 1 or 2;
- or a pharmaceutically acceptable salt thereof.


20

In one embodiment, the cancer is selected from triple negative breast cancer or glioblastoma multiforme. In one embodiment, the cancer is triple negative breast cancer. In one embodiment, the cancer is glioblastoma multiforme.

In some embodiments, the methods described herein are used for the treatment of the prevention of a cancer, for example, melanoma, lung cancer (including lung adenocarcinoma, basal cell carcinoma, squamous cell carcinoma, large cell carcinoma, bronchioloalveolar carcinoma, bronchogenic carcinoma, non-small-cell carcinoma, small cell carcinoma, mesothelioma); breast cancer (including triple negative breast cancer (TNBC), ductal carcinoma, lobular carcinoma, inflammatory breast cancer, clear cell carcinoma, mucinous carcinoma, serosal cavities breast carcinoma); colorectal cancer (colon cancer, rectal cancer, colorectal adenocarcinoma); anal cancer; pancreatic cancer (including pancreatic adenocarcinoma, islet cell carcinoma, neuroendocrine tumors); prostate cancer; prostate adenocarcinoma; ovarian carcinoma (ovarian epithelial carcinoma or surface epithelial-stromal tumor including serous tumor, endometrioid tumor and mucinous cystadenocarcinoma, sex-cord-stromal tumor); liver and bile duct carcinoma (including hepatocellular carcinoma, cholangiocarcinoma, hemangioma); esophageal carcinoma (including esophageal adenocarcinoma and squamous cell carcinoma); oral and oropharyngeal squamous cell carcinoma; salivary gland adenoid cystic carcinoma; bladder cancer; bladder carcinoma; carcinoma of the uterus (including endometrial adenocarcinoma, ocular, uterine papillary serous carcinoma, uterine clear-cell carcinoma, uterine sarcomas, leiomyosarcomas, mixed mullerian tumors); glioma, glioblastoma, medulloblastoma, and other tumors of the brain; kidney cancers (including renal cell carcinoma, clear cell carcinoma, Wilm's tumor); cancer of the head and neck (including squamous cell carcinomas); cancer of the stomach (gastric cancers, stomach adenocarcinoma, gastrointestinal stromal tumor); testicular cancer; germ cell tumor; neuroendocrine tumor; cervical cancer; carcinoids of the gastrointestinal tract, breast, and other organs; signet ring cell carcinoma; mesenchymal tumors including sarcomas, fibrosarcomas, haemangioma, angiomatosis, haemangiopericytoma, pseudoangiomatous stromal hyperplasia, myofibroblastoma, fibromatosis, inflammatory myofibroblastic tumor, lipoma, angioliipoma, granular cell tumor, neurofibroma, schwannoma, angiosarcoma, liposarcoma, rhabdomyosarcoma, osteosarcoma, leiomyoma, leiomyosarcoma, skin, including melanoma, cervical, retinoblastoma, head and neck cancer, pancreatic, brain, thyroid, testicular, renal, bladder, soft tissue, adenal gland, urethra, cancers of the penis, myxosarcoma, chondrosarcoma, osteosarcoma, chordoma, malignant fibrous histiocytoma, lymphangiosarcoma, mesothelioma, squamous cell carcinoma; epidermoid carcinoma, malignant skin adnexal tumors, adenocarcinoma, hepatoma, hepatocellular carcinoma, renal cell carcinoma, hypernephroma, cholangiocarcinoma, transitional cell carcinoma, choriocarcinoma, seminoma, embryonal cell carcinoma, glioma anaplastic; glioblastoma multiforme, neuroblastoma, medulloblastoma, malignant meningioma, malignant schwannoma, neurofibrosarcoma, parathyroid carcinoma, medullary carcinoma of thyroid, bronchial carcinoid, pheochromocytoma, Islet cell carcinoma,


malignant carcinoid, malignant paraganglioma, melanoma, Merkel cell neoplasm, cystosarcoma phylloide, salivary cancers, thymic carcinomas, and cancers of the vagina among others.

In one embodiment of the above methods, the compound administered is:




5

In another embodiment of the above methods, the compound administered is:



In another aspect, provided herein is a method for the treatment of a cancer, comprising: administering an effective amount of a compound to a host in need thereof, wherein the compound is:

10



Combinations Therapies - Additional Chemotherapeutic Agents

In one embodiment, a compound of Formula I, II, III, or IV is administered in combination
 5 with an additional chemotherapeutic agent. In one embodiment, disclosed herein is a composition comprising a compound of Formula I and an additional chemotherapeutic agent. In one embodiment, disclosed herein is a composition comprising a compound of Formula II and an additional chemotherapeutic agent. In one embodiment, disclosed herein is a composition comprising a compound of Formula III and an additional chemotherapeutic agent. In one
 10 embodiment, disclosed herein is a composition comprising a compound of Formula IV and an additional chemotherapeutic agent.

Additional chemotherapeutic agents include, but are not limited to, radioactive molecules, toxins, also referred to as cytotoxins or cytotoxic agents, which includes any agent that is detrimental to the viability of cells, agents, and liposomes or other vesicles containing
 15 chemotherapeutic compounds. Examples of suitable chemotherapeutic agents include but are not limited to 1-dehydrotestosterone, 5-fluorouracil decarbazine, 6-mercaptopurine, 6-thioguanine, actinomycin D, adriamycin, aldesleukin, alkylating agents, allopurinol sodium, altretamine, amifostine, anastrozole, anthramycin (AMC)), anti-mitotic agents, cis-dichlorodiamine platinum (II) (DDP cisplatin), diamino dichloro platinum, anthracyclines, antibiotics, antis, asparaginase,
 20 BCG live (intravesical), betamethasone sodium phosphate and betamethasone acetate, bicalutamide, bleomycin sulfate, busulfan, calcium leucouorin, calicheamicin, capecitabine, carboplatin, lomustine (CCNU), carmustine (BSNU), Chlorambucil, Cisplatin, Cladribine, Colchicin, conjugated estrogens, Cyclophosphamide, Cyclophosphamide, Cytarabine, Cytarabine,

cytochalasin B, Cytosan, Dacarbazine, Dactinomycin, dactinomycin (formerly actinomycin), daunirubicin HCL, daunorubicin citrate, denileukin diftitox, Dexrazoxane, Dibromomannitol, dihydroxy anthracin dione, Docetaxel, dolasetron mesylate, doxorubicin HCL, dronabinol, *E. coli* L-asparaginase, emetine, epoetin- α , *Erwinia* L-asparaginase, esterified estrogens, estradiol, 5 estramustine phosphate sodium, ethidium bromide, ethinyl estradiol, etidronate, etoposide citrororum factor, etoposide phosphate, filgrastim, floxuridine, fluconazole, fludarabine phosphate, fluorouracil, flutamide, folinic acid, gemcitabine HCL, glucocorticoids, goserelin acetate, gramicidin D, granisetron HCL, hydroxyurea, idarubicin HCL, ifosfamide, interferon α -2b, irinotecan HCL, letrozole, leucovorin calcium, leuprolide acetate, levamisole HCL, lidocaine, 10 lomustine, maytansinoid, mechlorethamine HCL, medroxyprogesterone acetate, megestrol acetate, melphalan HCL, mercaptopurine, mesna, methotrexate, methyltestosterone, mithramycin, mitomycin C, mitotane, mitoxantrone, nilutamide, octreotide acetate, ondansetron HCL, paclitaxel, pamidronate disodium, pentostatin, pilocarpine HCL, plimycin, polifeprosan 20 with carmustine implant, porfimer sodium, procaine, procarbazine HCL, propranolol, rituximab, 15 sargramostim, streptozotocin, tamoxifen, taxol, teniposide, tenoposide, testolactone, tetracaine, thioepa chlorambucil, thioguanine, thiotepa, topotecan HCL, toremifene citrate, trastuzumab, tretinoin, valrubicin, vinblastine sulfate, vincristine sulfate, and vinorelbine tartrate.

Additional chemotherapeutic agents or therapeutic agents that can be administered in combination with the compounds disclosed herein can include bevacizumab, sunitinib, sorafenib, 2-methoxyestradiol, finasunate, vatalanib, vandetanib, aflibercept, volociximab, etaracizumab, 20 cilengitide, erlotinib, cetuximab, panitumumab, gefitinib, trastuzumab, atacicept, rituximab, alemtuzumab, aldesleukine, atlizumab, tocilizumab, temsirolimus, everolimus, lucatumumab, dacetuzumab, atiprimod, natalizumab, bortezomib, carfilzomib, marizomib, tanespimycin, saquinavir mesylate, ritonavir, nelfinavir mesylate, indinavir sulfate, belinostat, panobinostat, 25 mapatumumab, lexatumumab, oblimersen, plitidepsin, talmapimod, enzastaurin, tipifarnib, perifosine, imatinib, dasatinib, lenalidomide, thalidomide, simvastatin, and celecoxib.

Compositions

Compositions, as described herein, comprising an active compound and an excipient of 30 some sort may be useful in a variety of applications. For example, pharmaceutical compositions comprising an active compound and an excipient may be useful for the treatment or prevention of a cancer, for example, triple negative breast cancer.

“Excipients” include any and all solvents, diluents or other liquid vehicles, dispersion or 35 suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.

General considerations in formulation and/or manufacture can be found, for example, in *Remington's Pharmaceutical Sciences*, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980), and *Remington: The Science and Practice of Pharmacy*, 21st Edition (Lippincott Williams & Wilkins, 2005).

5 Exemplary excipients include, but are not limited to, any non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as excipients include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; 10 powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as Tween 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate 15 buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator. As would be appreciated by one of skill in this art, the excipients may be chosen based on what the composition is useful for. For example, 20 with a pharmaceutical composition or cosmetic composition, the choice of the excipient will depend on the route of administration, the agent being delivered, time course of delivery of the agent, etc., and can be administered to humans and/or to animals, orally, rectally, parenterally, intracisternally, intravaginally, intranasally, intraperitoneally, topically (as by powders, creams, ointments, or drops), buccally, or as an oral or nasal spray.

25 Exemplary diluents include calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and combinations thereof.

30 Exemplary granulating and/or dispersing agents include potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch,

water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (Veegum), sodium lauryl sulfate, quaternary ammonium compounds, etc., and combinations thereof.

Exemplary surface active agents and/or emulsifiers include natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65], glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof.

Exemplary binding agents include starch (e.g. cornstarch and starch paste), gelatin, sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol, etc.), natural and synthetic gums (e.g. acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (Veegum), and larch arabogalactan), alginates, polyethylene oxide, polyethylene glycol, inorganic calcium salts, silicic acid, polymethacrylates, waxes, water, alcohol, etc., and/or combinations thereof.

Exemplary preservatives include antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and other preservatives.

Exemplary antioxidants include alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and sodium sulfite.

5 Exemplary chelating agents include ethylenediaminetetraacetic acid (EDTA) and salts and hydrates thereof (e.g., sodium edetate, disodium edetate, trisodium edetate, calcium disodium edetate, dipotassium edetate, and the like), citric acid and salts and hydrates thereof (e.g., citric acid monohydrate), fumaric acid and salts and hydrates thereof, malic acid and salts and hydrates thereof, phosphoric acid and salts and hydrates thereof, and tartaric acid and salts and hydrates thereof. Exemplary antimicrobial preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and thimerosal.

15 Exemplary antifungal preservatives include butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and sorbic acid.

Exemplary alcohol preservatives include ethanol, polyethylene glycol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and phenylethyl alcohol.

20 Exemplary acidic preservatives include vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroacetic acid, ascorbic acid, sorbic acid, and phytic acid.

Other preservatives include tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, Glydant Plus, Phenonip, methylparaben, Germall 115, Germaben II, Neolone, Kathon, and Euxyl. In certain embodiments, the preservative is an anti-oxidant. In other embodiments, the preservative is a chelating agent.

Exemplary buffering agents include citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium gluconate, calcium gluceptate, calcium gluconate, D-gluconic acid, calcium glycerophosphate, calcium lactate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium

35

phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol, etc., and combinations thereof.

Exemplary lubricating agents include magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, etc., and combinations thereof.

Exemplary natural oils include almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils. Exemplary synthetic oils include, but are not limited to, butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and combinations thereof.

Additionally, the composition may further comprise a polymer. Exemplary polymers contemplated herein include, but are not limited to, cellulosic polymers and copolymers, for example, cellulose ethers such as methylcellulose (MC), hydroxyethylcellulose (HEC), hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), methylhydroxyethylcellulose (MHEC), methylhydroxypropylcellulose (MHPC), carboxymethyl cellulose (CMC) and its various salts, including, e.g., the sodium salt, hydroxyethylcarboxymethylcellulose (HECMC) and its various salts, carboxymethylhydroxyethylcellulose (CMHEC) and its various salts, other polysaccharides and polysaccharide derivatives such as starch, dextran, dextran derivatives, chitosan, and alginic acid and its various salts, carageenan, various gums, including xanthan gum, guar gum, gum arabic, gum karaya, gum ghatti, konjac and gum tragacanth, glycosaminoglycans and proteoglycans such as hyaluronic acid and its salts, proteins such as gelatin, collagen, albumin, and fibrin, other polymers, for example, polyhydroxyacids such as polylactide, polyglycolide, poly(lactide-co-glycolide) and poly(epsilon-caprolactone-co-glycolide)-, carboxyvinyl polymers and their salts (e.g., carbomer), polyvinylpyrrolidone (PVP), polyacrylic acid and its salts, polyacrylamide, polyacilic acid/acrylamide copolymer, polyalkylene oxides such as polyethylene oxide,

polypropylene oxide, poly(ethylene oxide-propylene oxide), and a Pluronic polymer, polyoxyethylene (polyethylene glycol), polyanhydrides, polyvinylalcohol, polyethyleneamine and polypyridine, polyethylene glycol (PEG) polymers, such as PEGylated lipids (e.g., PEG-stearate, 1,2-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-1000], 1,2-
5 Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000], and 1,2-Distearoyl-sn-glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-5000]), copolymers and salts thereof.

Additionally, the composition may further comprise an emulsifying agent. Exemplary emulsifying agents include, but are not limited to, a polyethylene glycol (PEG), a polypropylene
10 glycol, a polyvinyl alcohol, a poly-N-vinyl pyrrolidone and copolymers thereof, poloxamer nonionic surfactants, neutral water-soluble polysaccharides (e.g., dextran, Ficoll, celluloses), non-cationic poly(meth)acrylates, non-cationic polyacrylates, such as poly(meth)acrylic acid, and esters amide and hydroxyalkyl amides thereof, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool
15 fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and Veegum [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl
20 polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [Tween 20], polyoxyethylene sorbitan [Tween 60], polyoxyethylene sorbitan monooleate [Tween 80], sorbitan monopalmitate [Span 40], sorbitan monostearate [Span 60], sorbitan tristearate [Span 65],
25 glyceryl monooleate, sorbitan monooleate [Span 80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [Myrj 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and Solutol), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. Cremophor), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [Brij 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate,
30 triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, Pluronic F 68, Poloxamer 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, etc. and/or combinations thereof. In certain embodiments, the emulsifying agent is cholesterol.

Liquid compositions include emulsions, microemulsions, solutions, suspensions, syrups,
35 and elixirs. In addition to the active compound, the liquid composition may contain inert diluents

commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

Injectable compositions, for example, injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a injectable solution, suspension, or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents for pharmaceutical or cosmetic compositions that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. Any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. In certain embodiments, the particles are suspended in a carrier fluid comprising 1% (w/v) sodium carboxymethyl cellulose and 0.1% (v/v) Tween 80. The injectable composition can be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

Compositions for rectal or vaginal administration may be in the form of suppositories which can be prepared by mixing the particles with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the particles.

Solid compositions include capsules, tablets, pills, powders, and granules. In such solid compositions, the particles are mixed with at least one excipient and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid

polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

5 Tablets, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances
10 and waxes.

 Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

 Compositions for topical or transdermal administration include ointments, pastes, creams,
15 lotions, gels, powders, solutions, sprays, inhalants, or patches. The active compound is admixed with an excipient and any needed preservatives or buffers as may be required.

 The ointments, pastes, creams, and gels may contain, in addition to the active compound, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc, and zinc oxide, or
20 mixtures thereof.

 Powders and sprays can contain, in addition to the active compound, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.

25 Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the nanoparticles in a proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the particles in a polymer matrix or gel.

30 The active ingredient may be administered in such amounts, time, and route deemed necessary in order to achieve the desired result. The exact amount of the active ingredient will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular active ingredient, its mode of administration, its mode of activity, and the like. The active ingredient, whether the active compound itself, or the active
35 compound in combination with an agent, is preferably formulated in dosage unit form for ease of

administration and uniformity of dosage. It will be understood, however, that the total daily usage of the active ingredient will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the active ingredient employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific active ingredient employed; the duration of the treatment; drugs used in combination or coincidental with the specific active ingredient employed; and like factors well known in the medical arts.

The active ingredient may be administered by any route. In some embodiments, the active ingredient is administered via a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical (as by powders, ointments, creams, and/or drops), mucosal, nasal, bucal, enteral, sublingual; by intratracheal instillation, bronchial instillation, and/or inhalation; and/or as an oral spray, nasal spray, and/or aerosol. In general the most appropriate route of administration will depend upon a variety of factors including the nature of the active ingredient (e.g., its stability in the environment of the gastrointestinal tract), the condition of the subject (e.g., whether the subject is able to tolerate oral administration), etc.

The exact amount of an active ingredient required to achieve a therapeutically or prophylactically effective amount will vary from subject to subject, depending on species, age, and general condition of a subject, severity of the side effects or disorder, identity of the particular compound(s), mode of administration, and the like. The amount to be administered to, for example, a child or an adolescent can be determined by a medical practitioner or person skilled in the art and can be lower or the same as that administered to an adult.

EXAMPLES

The following examples are set forth below to illustrate the compounds, compositions, methods, and results according to the disclosed subject matter. These examples are not intended to be inclusive of all aspects of the subject matter disclosed herein, but rather to illustrate representative methods and results. These examples are not intended to exclude equivalents and variations of the present invention which are apparent to one skilled in the art.

Example 1. Potent and Selective Indolinone Derivatives that Inhibit Maternal Embryonic Leucine Zipper Kinase (MELK) and Inhibit Triple Negative Breast Cancer (TNBC) Cell Growth

Despite recent advances in molecularly directed therapy, triple negative breast cancer (TNBC) remains one of the most aggressive forms of breast cancer still without a suitable target for specific inhibitors. Maternal embryonic leucine zipper kinase (MELK) is highly expressed in TNBC where the level of overexpression correlates with poor prognosis and an aggressive disease course. This example describes the identification of a series of ATP-competitive indolinone derivatives with subnanomolar inhibition constants towards MELK. The most potent compound inhibits the proliferation of TNBC cells and exhibits a selectivity for cells expressing high levels of MELK.

In contrast to most members of the AMPK-RK family, which mediate cell survival under stressful metabolic conditions (Gil M, et al. *Gene*. 1997;195(2):295-301; Beullens M, et al. *The Journal of biological chemistry*. 2005;280(48):40003-40011). MELK has been implicated in multiple cellular processes, including cell cycle checkpoint regulation (Blot J, et al. *Dev Biol*. 2002;241(2):327-338; Davezac N, et al. *Oncogene*. 2002;21(50):7630-7641), proliferation (Joshi K, et al. *Stem cells (Dayton, Ohio)*. 2013; Saito R, et al. *Cancer science*. 2012;103(1):42-49), apoptosis (Lin ML, et al. *Breast cancer research: BCR*. 2007;9(1):R17; Pickard MR, et al. *Biochimica et biophysica acta*. 2011;1812(9):1146-1153), and RNA processing (Vulsteke V, et al. *The Journal of biological chemistry*. 2004;279(10):8642-8647). MELK is expressed in the early stages of murine embryonic development (Heyer BS, et al. *Molecular reproduction and development*. 1997;47(2):148-156), but MELK knockout mice develop normally with no obvious pathologic phenotype, suggesting that MELK's developmentally-related functions may be redundant (Wang Y, et al. *eLife*. 2014:e01763). Yet despite its apparent dispensable nature in differentiated adult cells, evidence has implicated MELK's importance in proliferating progenitor populations, including multipotent neural progenitors (Nakano I, et al. *The Journal of cell biology*. 2005;170(3):413-427), myoblasts (Niesler CU, et al. *Experimental physiology*. 2007;92(1):207-217), and mammary progenitors (Hebbard LW, et al. *Cancer research*. 2010;70(21):8863-8873). Interestingly, MELK inhibition does not affect survival in normal neural stem cells, but siRNA-mediated MELK knockdown induces apoptosis selectively in glioma stem cells (Nakano I, et al. *Neuro-oncology*. 2011;13(6):622-634; Nakano I, et al. *Journal of neuroscience research*. 2008;86(1):48-60). Such data reinforces the redundancy of MELK function in noncancerous cells, but also implicates the existence of an exploitable target in certain cancer stem cell populations.

In addition to its putative role in cancer stem cells, upregulated MELK mRNA and protein levels have been observed in a wide array of cancer cell types and clinical tumor samples (Gray D, et al. *Cancer research*. 2005;65(21):9751-9761; Ryu B, et al. *PloS one*. 2007;2(7):e594; Marie SK, et al. *International journal of cancer. Journal international du cancer*. 2008;122(4):807-815; Li Y, et al. *Lung cancer (Amsterdam, Netherlands)*. 2013; Li Y, et al. *Lung cancer (Amsterdam, Netherlands)*. 2013; Rajkumar T, et al. *BMC cancer*. 2011;11:80; Risinger JI, et al. *Frontiers in*

oncology. 2013;3:139). Of particular note is the fact that MELK expression correlates with poor prognosis in the most aggressive subsets of disease, including glioblastoma multiforme (GBM) (Nakano I, et al. Journal of neuroscience research. 2008;86(1):48-60; Marie SK, et al. International journal of cancer. Journal international du cancer. 2008;122(4):807-815; Kappadakunnel M, et al. 5 Journal of neuro-oncology. 2010;96(3):359-367) and triple negative breast cancer (TNBC) (Wang Y, et al. eLife. 2014:e01763; Komatsu M, et al. International journal of oncology. 2013;42(2):478-506; Al-Ejeh F, et al. Oncogenesis. 2014;3:e100). Factors contributing to poor outlook for TNBC patients in part stems from the cancer's ability not only to proliferate quickly, but also its propensity to spread and recur in distant organs. From a molecular biology perspective, mounting 10 evidence continues to implicate MELK in direct and transcriptional regulation of cell division in the context of malignancy (Joshi K, et al. Stem cells (Dayton, Ohio). 2013; Wang Y, et al. eLife. 2014:e01763; Marie SK, et al. Proteome Sci. 2016;14:6). Furthermore, MELK has also been preliminarily linked to metastasis through its involvement with TGF- β driven epithelial-to-mesenchymal transition (EMT) (Seong HA, et al. The Journal of biological chemistry. 15 2010;285(40):30959-30970). The cancer-specific expression pattern, combined with the clinical and biological data have therefore justifiably fostered strong interest in MELK as a clinical target.

The present example discloses novel chemical probes to inhibit MELK and small molecule therapeutics that can target a cancer (for example, TNBC). To that end, the design and development of a new structural class of highly potent indolinone MELK inhibitors is described 20 in this example, including compounds **16**, **17**, and **21**, with subnanomolar inhibition constants (K_i). In addition to potency, the new class of inhibitors disclosed herein show selectivity for MELK relative to other functionally and evolutionarily related kinases. Finally, these inhibitors were applied to relevant TNBC cell lines. It was observed that the inhibitors impact TNBC cell viability and proliferation, with little effect on an immortalized breast epithelial cell line which does not 25 express high levels of MELK.





Over the last two decades, protein kinases have represented a major field for drug development. As such, diverse methods of kinase inhibitor discovery have emerged and have been extensively employed in both the industrial and academic settings. Target-centric strategies focus on screening small molecule libraries against a single kinase of interest, whereas compound-centric approaches 30 profile activities of a single compound against the entire kinome (Miduturu CV, et al. Chemistry & biology. 2011;18(7):868-879). Within the target-centric method, screening libraries may take on the form of fragment-based, directed, or diverse high-throughput compound collections.







In addition to addressing selectivity, cross-screening has become increasingly utilized as a means of drug discovery. Cross-screening unearths off-target effects in cases where inhibitory 35 properties of the small molecules are characterized (e.g. single known kinase inhibitor or directed

kinase inhibitor libraries) (Uitdehaag JC, et al. *Br J Pharmacol.* 2012;166(3):858-876). Such off-target activity then serves as an initial starting point for development of untargeted or under-targeted kinase inhibitors (Mathea S, et al. *ACS Chem Biol.* 2016;11(6):1595-1602; Elkins JM, et al. *Nat Biotechnol.* 2016;34(1):95-103). Alternatively, compound-centric approaches may also be used to improve selectivity of the primary compound, engineering out inhibition of particular undesired targets (Mathea S, et al. *ACS Chem Biol.* 2016). In each of the above strategies, structural guidance is typically essential at every stage to provide critical insight for scaffold modification.

To date, no inhibitors developed with MELK as a primary target are FDA approved. Thus, as an initial experiment, a curated library of approximately 800 known kinase inhibitors in duplicate plate format was examined for ability to inhibit MELK as an off-target. Compounds were ranked according to average percent inhibition at both 10 and 1 μ M, revealing 18 compounds with $\geq 50\%$ inhibition at 1 μ M. The ten most potent compounds were further characterized by determining each compound's respective IC_{50} (Table 4). The indolinone scaffold or a similar bicyclic core structure populated the top hits. Indeed, indolinone motifs represent a common pharmacophore in ATP-competitive inhibitors (Prakash CR, et al. *Mini reviews in medicinal chemistry.* 2012;12(2):98-119; Aronov AM, et al. *Journal of medicinal chemistry.* 2008;51(5):1214-1222).

Table 4. Cross-inhibition of MELK by known kinase inhibitors

Compound	Structure	Core	$IC_{50} \pm SE$ (nM)
Nintedanib		Indolinone	43 ± 3.4
Hesperadin		Indolinone	225 ± 50
420099		Benzimidazo-isoquinolinone	330 ± 37
CC401		Indazole	340 ± 70

Compound	Structure	Core	IC ₅₀ ± SE (nM)
PIK75		Imidazopyridine	400 ± 72
HA-1004		Isoquinoline	440 ± 210
AT9283		Benzimidazole	685 ± 125
527450		Indolinone	720 ± 100
572660		Indolinone	760 ± 190
AZD776		Thiofuran	900 ± 91

The most potent of the top inhibitor candidates was nintedanib (BIBF-1120, Vargatef[®]/Ofev[®]), which displayed an IC₅₀ of 43 nM. Nintedanib is already FDA-approved for the treatment of idiopathic pulmonary fibrosis and is currently undergoing clinical trials for treatment of non-small cell lung cancer, metastatic colorectal cancer, and ovarian cancer.

- 5 However, it is a multi-kinase inhibitor whose primary described mechanism of action is inhibition of the growth factor receptors VEGFR, PDGFR, and FGFR. To improve upon nintedanib's potency and selectivity towards MELK, a medicinal chemistry program was designed around its structural features, using the indolinone core as a primary scaffold.


10 While nintedanib was clearly the most potent molecule, (IC₅₀ = 43 nM), additional observations from the screen also directed the medicinal chemistry design strategy. The top three most potent inhibitors all exhibit a common alternating donor/acceptor hydrogen-bonding pattern that has also been observed with previously published inhibitors (Figure 1). Heteroatoms and substituents of the bicyclic core are spatially oriented to interact with both the hinge region and the conserved catalytic lysine, respectively. In addition to nintedanib, an indolinone scaffold forms

the core of three other candidate compounds (Table 4, entries 2, 8, and 9), while others contained similar heterocyclic motifs. Notably, several of the indolinones contain substituents at the 5- or 6-position, which are predicted through modeling studies to interact via hydrogen bonding with Lys 40 of the binding pocket.

5 Molecular modeling studies using Gold 5.1 (Cambridge Crystallographic Data Center) reinforce the similarities in binding pose and electrostatic contacts between nintedanib and other published inhibitors (Figure 2). In the hinge region, the backbone of C89 interacts with the enamine nitrogen and the carbonyl of the indolinone ring of nintedanib (Figure 2A), mirroring the hydrogen bonding pattern seen in the crystal structure of MELK with Cpd2 (Figure 2B, PDB
10 4BKY) (Canevari G, et al. *Biochemistry*. 2013;52(37):6380-6387). With both nintedanib and Cpd2, K40 is positioned to interact with bicyclic core substituents, either directly or via a water molecule. Interaction with K40 has been previously described as an “activity cliff” with other MELK inhibitors, in that loss of this interaction results in loss of compound activity towards
15 MELK (Toure BB, et al. *J Med Chem*. 2016;59(10):4711-4723; Furtmann N, et al. *J Med Chem*. 2015;58(1):252-264). Taken together, the screening and modeling data suggest that MELK not only accommodates various substituents at the 5th and 6th positions of the indolinone ring, but also that it may be a critical element for maintaining inhibitor potency. Thus, a derivative library incorporating 5- and 6-substituted indolinone inhibitors was synthesized.

20 **Synthesis of 5, or 6-substituted indolinone derivatives 15–25**


After identifying the MELK inhibitor compounds in Table 4, a number of 5, or 6-substituted indolinone derivatives were then synthesized in order to improve potency and selectivity (See Compounds **15–25**). The general synthetic routes are outlined in Schemes 1 and 2. The key intermediates **6–10** were prepared by acylation of indolinones **1–5** and subsequent
25 condensation with *ortho*-benzoic acid triethylester. Aromatic amine intermediate **14** was prepared by literature procedures as illustrated in Scheme 1 (Roth GJ, et al. *J Med Chem*. 2009;52(14):4466-4480). Acylation of *N*-methyl-4-nitroaniline **11** gave chloroacetyl amide **12**, which was then treated with *N*-methylpiperazine to displace chloride; followed by catalytic reduction of the nitro group which gave the key aromatic amine intermediate **14**.



Scheme 1.

Synthesis of intermediates. Reagents and conditions: (a) Ac₂O, 130 °C, 8 h; (b) PhC(OEt)₃, Ac₂O, 120 °C, 6 h, 46–51% (for two steps a and b); (c) AcCl, AlCl₃, 1,2-dichloroethane, below 10 °C, 1 h then RT, 12 h 72%; (d) chloroacetyl chloride, ethyl acetate, 70 °C, 1 h, 90%; (e) *N*-methylpiperazine, toluene, 55 °C, 2 h; (f) Pd/C, H₂, ⁱPr-OH, RT, 12 h, 76% (for two steps e and f).

Final indolinone analogs **15–19** were prepared by addition of **14** to substituted indolinones **6–10** and subsequent elimination of ethanol, followed by acetyl cleavage using piperidine in one pot (Scheme 2). Additional 5 or 6-substituted amide analogs **22–25** were synthesized from the corresponding 5 or 6-substituted methyl ester derivatives by hydrolysis using aqueous 1 N NaOH and subsequent standard amide coupling reactions using *N*-methyl amine and *N,N*-dimethylamine after TBTU or HBTU activation (Scheme 2). The 5, or 6-substituted indolinone derivatives **15–25** in Table 5 were evaluated for their ability to inhibit MELK.



Scheme 2.

- 5 **Synthesis of final compounds.** Reagents and conditions: (g) DMF, 80–100 °C, 1 h; (h) piperidine, RT, 63–73% (for two steps g and h); (i) 1N aq. NaOH, dioxane:methanol (1:1), 80 °C, 5 h; (j) an amine reactant, TBTU or HBTU, HOBT, DIPEA, DMF, RT.

5-substituted indolinone derivatives improve potency towards MELK

- 10 First, efforts were focused on 6-substituted indolinone derivatives. After synthesizing nintedanib (**15**), the methyl ester was hydrolyzed to the carboxylic acid **20**. Longer amines were also synthesized containing amides **22** and **23** (similar to the amine motif in the known MELK inhibitor **Cpd1** (Canevari G, et al. Biochemistry. 2013;52(37):6380-6387). Unfortunately, all the 6-substituted indolinone derivatives were found to be less potent compared to the lead compound
- 15 **15** (Table 5). Next, attention was shifted to the 5th position of the indolinone ring. Initial compounds synthesized included 5-substituted methyl ester, methyl ketone and fluoro indolinones **17–19**. Surprisingly, both 5-CO₂Me **17** ($K_i = 0.39$ nM) and 5-F derivative **19** ($K_i = 3.1$ nM) were found to be more potent compared to the lead compound **15** ($K_i = 5.6$ nM). Further, the unsubstituted indolinone **16** was also found to be active ($K_i = 0.47$ nM), challenging the notion
- 20 that the 5 or 6-substituents are critical for binding MELK. Hydrolysis of the methyl ester produced inhibitor **19** which retained MELK activity ($K_i = 0.68$ nM). 5-substituted amide analogs **24** ($K_i = 2.3$ nM) and **25** ($K_i = 8.8$ nM) showed lower activities compared to the 5-methyl ester analog **17**




Table 6. Fragment and intermediate potency (K_i's of synthetic intermediates)

Compound	K _i ± SD (nM)
6	> 650
8	> 650
14	> 650
15	84 ± 13


To further understand the substantial increase in potency by shifting the methyl ester from the 6 to the 5 position, both compound **15** (6-CO₂Me) and compound **17** (5-CO₂Me) were docked with MELK (PDB: 4BKY) and analyzed using Gold5.2 with the ChemPLP scoring function. The methyl ester substituents of both compounds are within direct or water-bridged hydrogen bonding distance of K40 (Figure 3). A methyl ester in the 5th position, however is predicted to force **17** deeper into the narrow groove leading to K40. This would likely shorten the H-bond distance, and strengthen the interaction. Moreover, this modification enables **17** to adopt a conformation more complementary to the shape of the binding pocket, facilitating the interaction of the indolinone core with E87 through an additional hydrogen bond. Concordantly, retained potency of **16** (unsubstituted indolinone) suggests that suboptimal substituent position significantly affects inhibitor binding. Alternatively, the potency of **16** may also be explained by the ability of an unsubstituted indolinone to adopt a greater number of binding modes.

MELK derivatives show differential selectivity towards functionally related kinases

In light of the same chemical reaction they all perform, kinases by definition have a characteristic binding site for ATP. While critical residues must be present for the phosphoryl transfer reaction (e.g., those to coordinate magnesium ions and the phosphoester chain), there is considerable diversity in residues that additionally influence the volume and shape of the ATP binding pocket, giving rise to the possibility of kinase inhibitor selectivity. Such parameters not

only determine how tightly an enzyme can bind ATP, but also dictate what small molecules will effectively compete with ATP and take advantage of unique surface complementarities. Therefore, these new inhibitors were investigated in the context of inhibiting MELK's most closely related family members AMPK and NUAK1. It was also determined whether the most potent
 5 MELK inhibitor derivatives affected other kinases involved in putative MELK-related pathways (the cell cycle and CHK1), or those driving certain AMPK-RK signaling pathways (CAMKKII). In contrast, ERK2 served as an unrelated control.

The top three most potent MELK inhibitor derivatives, compounds **16**, **17**, and **21**, were analyzed in dose-response inhibition assays and used apparent K_M^{ATP} values determined under our
 10 experimental conditions to calculate K_i (Table 8). Compound **16**, which contains no substituent at either the 5- or 6-position of the indolinone, was the least selective inhibitor of the three (Table 7). Compound **16** inhibited both AMPK and NUAK1 quite well, resulting in only a 5–10 fold difference in K_i compared to MELK. Addition of a methyl ester at the 5-position (compound **17**) resulted in comparable potency towards MELK, but increased selectivity towards other kinases.
 15 Hydrolysis of the methyl ester to the carboxylate (compound **21**) yielded the best selectivity profile of the three inhibitors tested, displaying > 100-fold difference in relative K_i compared to MELK for CHK1, CAMKK2, and ERK2. All three compounds remained fairly tight binding inhibitors of closely related kinases AMPK and NUAK1.



20 **Table 7. Selectivity of MELK inhibitor derivatives against selected kinases.**

Kinase	Compound 16		Compound 17		Compound 21	
	K_i	φ^a	K_i	φ^a	K_i	φ^a
MELK	0.47 ± 0.06	1.00	0.39 ± 0.09	1.00	0.68 ± 0.07	1.00
AMPK	4.2 ± 0.3	8.9 ± 0.2	9.2 ± 1.7	24 ± 0.3	4.9 ± 0.6	7.2 ± 0.2
NUAK1	1.7 ± 0.17	3.6 ± 0.2	11 ± 0.86	28 ± 0.2	8.6 ± 1.6	13 ± 0.2
CHK1	10 ± 0.5	18 ± 0.2	7 ± 0.17	18 ± 0.2	81 ± 5.6	120 ± 0.1
CAMKK2	15 ± 1.8	32 ± 0.2	31 ± 11	80 ± 0.4	85 ± 9.2	125 ± 0.2
ERK2	1160 ± 320	2500 ± 0.3	3000 ± 1300	7700 ± 0.5	19000 ± 3800	28000 ± 0.2

$$^a\varphi = K_i^{\text{Enzyme}} / K_i^{\text{MELK}}$$

While not appreciably affecting potency towards MELK, additional negative charge at the 5-position enhances compound selectivity. Such a trend is particularly apparent in the case of
5 CHK1. MELK has been implicated in regulation of the cell cycle through inhibitory phosphorylation of the phosphatase CDC25B, whose main function is to promote mitotic entry through dephosphorylation and activation of CDK1/cyclin B (Davezac N, et al. *Oncogene*. 2002;21(50):7630-7641). It has additionally been reported that MELK overexpression may increase DNA damage and replication stress tolerance in cancer cells, as MELK inhibition resulted
10 in a prolonged ATM-CHK2 response (Beke L, et al. *Biosci Rep*. 2015). The reported roles of MELK in cancer cells therefore suggest potential intimate relation with those functions of CHK1. Thus, a MELK inhibitor that affords additional selectivity against CHK1, like compound **21**, is a valuable tool for further delineation of MELK's role in the context of cell division and DNA damage and repair. Finally, it should be noted that while Compound **17** is the most potent *in vitro*,
15 it is possible that its methyl ester is hydrolyzed *in vivo* due to the prevalence of esterases at the cellular and whole organism level. Thus, not only is compound **21** the most selective of the three, it is also a likely potent species present to inhibit MELK in a living system.

Inhibitor 17 decreases cell proliferation of TNBC cells

20 As MELK was found to be essential in basal-like breast cancer cells (Wang Y, et al. *eLife*. 2014:e01763), the CellTiter-Blue assay was used to test the ability of two compounds (**17** and **19**, Figure 4A) to inhibit the proliferation of various TNBC subtypes (Lehmann BD, et al. *The Journal of clinical investigation*. 2011;121(7):2750-2767), HCC70 (BL2 subtype), BT-549 (mesenchymal) and SUM-159 (mesenchymal stem-like), as well as the immortalized mammary epithelial cell line
25 MCF10A (classified as Basal B by molecular profiling) (Kao J, et al. *PloS one*. 2009;4(7):e6146). Proliferation of the HCC70, BT-549, and SUM-159 cells were clearly impacted by treatment with **17**, whereas the MCF10A cells remained largely unaffected at 10 μ M. In contrast, **19**, inhibited all cell lines. Such data is congruent with our previous results (Table 5), as **17** is around 10 fold more potent than the 5-fluoro derivative **19** *in vitro*, and **17** is a more effective inhibitor of
30 proliferation in cells. The ability of **19** to inhibit proliferation in MCF10A cells may be explained by the fact that 5-fluoro derivative may be less selective, much like the unsubstituted indolinone **16**. Furthermore, cell lines expressing high levels of MELK protein (HCC70 and BT549) were more sensitive to **17** than those cells with low levels of MELK expression (SUM159). Collectively, these data show that **17** selectively inhibits proliferation of TNBC cells expressing
35 high levels of MELK.

Summary

In conclusion, 5-substituted indolinones were identified as a novel MELK inhibitor scaffold though targeted kinase library inhibitor screening. Derivatization of the most potent MELK inhibitor identified in the initial screen (nintedanib) led to three tightly binding MELK inhibitors with subnanomolar inhibition constants (compounds **16**, **17**, and **21**). The unsubstituted indolinone was the least selective against a small subset of evolutionarily and functionally related kinases. However, compound **21** afforded selectivity against 3 out of 5 kinases tested, particularly against the mitotic kinase CHK1. The most potent MELK inhibitor, compound **17**, decreases viability and proliferation of multiple TNBC cell lines with high MELK expression. Conversely, compound **17** shows little effect on low MELK-expressing MCF-10A cells, an immortalized breast epithelial cell line.

Methods

15 Chemistry

General Information. Reagents and starting materials including indolinones **1–3**, and **5**, and *N*-Methyl-4-nitroaniline **11** were purchased from various commercial sources including Sigma-Aldrich or Matrix Scientific and used without further purification unless otherwise stated. 5-Acetylindolinone **4** and aromatic amine intermediate **14** were prepared by literature procedures (Roth GJ, et al. J Med Chem. 2009;52(14):4466-4480; Heckel AB, et al. Inventor; Boehringer Ingelheim International GmbH (Ingelheim, DE), assignee. Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments. 2007). All reactions were carried out in oven- or flame-dried glassware under argon. Thin-layer chromatography (TLC) was performed using pre-coated TLC plates with silica gel 60 F₂₅₄ (EMD) or with aluminum oxide 60 F₂₅₄ neutral. Flash column chromatography was performed using 40–63 μm (230–400 mesh ASTM) silica gel (EMD). Melting points were recorded on a Thomas Hoover capillary melting point apparatus. NMR spectra were recorded on a Varian MR spectrometer. High-resolution mass and liquid chromatography mass spectral data were obtained at the University of Texas at Austin. Compounds were characterized by NMR and HRMS or LCMS.

5-Acetylindolin-2-one (4). By following acylation procedure reported in a patent (Heckel AB, et al. Inventor; Boehringer Ingelheim International GmbH (Ingelheim, DE), assignee. Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments. 2007). 5-acetylindolin-2-one was prepared from indolin-2-one and AlCl₃. The crude was recrystallized from ethyl acetate to obtain 72% of the title compound. ¹H NMR (400 MHz, DMSO-

d_6): δ 10.76 (br s, 1H, NH), 7.85 (m, 1H, Ar-H), 7.80 (m, 1H, Ar-H), 6.90 (d, J = 8.0 Hz, 1H, Ar-H), 3.55 (s, 2H), 2.50 (s, 3H, Ac).

General procedure for the synthesis of *N*-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindolines (Compounds **6–10**). **Methyl (*Z*)-1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate (**6**)** (Roth GJ, et al. J Med Chem. 2009;52(14):4466-4480). Indolinone **1** (1000 mg, 52.3 mmol) was suspended in acetic anhydride (10 mL) and refluxed at 130 °C for 8 h. The reaction mixture was allowed to cool to 50 °C and (triethoxymethyl)benzene (2930 mg, 131 mmol) was added. The resulting reaction mixture was stirred at 120 °C for 6 h. Then, volatiles were removed *in vacuo* and petroleum ether was added to the obtained residue. After triturating for 15 minutes, the separated solids were filtered and washed with petroleum ether and then dried under vacuum to afford 974 mg (51%) of title compound. ^1H NMR (400 MHz, DMSO- d_6): δ 8.75 (s, 1H), 8.10 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.49–7.58 (m, 5H), 4.01 (q, J = 7.2 Hz, 2H), 3.87 (s, 3H), 2.44 (s, 3H), 1.35 (t, J = 8.0 Hz, 3H). HRMS m/z found 365.1260, calcd for $\text{C}_{21}\text{H}_{19}\text{NO}_5$ $[\text{M}]^+$ 365.1263.

(*Z*)-1-acetyl-3-(ethoxy(phenyl)methylene)indolin-2-one (7**)**. The title compound was synthesized in 46% yield using similar procedure as described for the synthesis of compound **6** by swapping indolinone **2** for indolinone **1**. Major conformer ^1H NMR (400 MHz, DMSO- d_6): δ 8.17–8.13 (m, 1H), 8.02–7.99 (m, 1H), 7.56–7.46 (m, 5H), 7.30–7.22 (m, 2H), 3.94 (q, J = 7.2 Hz, 2H), 2.43 (s, 3H), 1.33 (t, J = 7.4 Hz, 3H). LCMS m/z found 308.1, calcd for $\text{C}_{19}\text{H}_{18}\text{NO}_3$ $[\text{M}+\text{H}]^+$ 308.1.

Methyl (*Z*)-1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-5-carboxylate (8**)**. The title compound was synthesized in 48% yield using similar procedure as described for the synthesis of compound **6** by swapping indolinone **3** for indolinone **1**. ^1H NMR (400 MHz, DMSO- d_6): δ 8.61 (d, J = 1.6 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.92 (dd, J = 8.4 Hz, J = 1.6 Hz, 1H), 7.58–7.49 (m, 5H), 3.99 (q, J = 7.0 Hz, 2H), 3.87 (s, 3H), 2.45 (s, 3H), 1.37 (t, J = 7.0 Hz, 3H). HRMS m/z found 346.1058, calcd for $\text{C}_{19}\text{H}_{17}\text{NNaO}_4$ $[\text{M}-\text{Ac}+\text{Na}]^+$ 346.1055.

(*Z*)-1,1'-(3-(Ethoxy(phenyl)methylene)-2-oxoindoline-1,5-diyl)bis(ethan-1-one) (9**)**. The title compound was synthesized in 47% yield using similar procedure as described for the synthesis of compound **6** by swapping indolinone **4** for indolinone **1**. ^1H NMR (400 MHz, DMSO- d_6): δ 8.58 (d, J = 2.0 Hz, 1H), 8.23 (d, J = 8.4 Hz, 1H), 7.94 (dd, J = 8.4 Hz, J = 2.0 Hz, 1H), 7.58–7.49 (m, 5H), 3.99 (q, J = 7.0 Hz, 2H), 2.61 (s, 3H), 2.45 (s, 3H), 1.39 (t, J = 8.0 Hz, 3H). LCMS m/z found 350.1, calcd for $\text{C}_{21}\text{H}_{20}\text{NO}_4$ $[\text{M}+\text{H}]^+$ 350.1.

(*Z*)-1-acetyl-3-(Ethoxy(phenyl)methylene)-5-fluoroindolin-2-one (10**)**. The title compound was synthesized in 48% yield using similar procedure as described for the synthesis of compound **6** by swapping indolinone **5** for indolinone **1**. Major conformer ^1H NMR (400 MHz,

DMSO-*d*₆): δ 8.16 (m, 1H), 7.71(m, 1H), 7.57–7.47 (m, 5H), 7.12 (m, 1H), 3.98 (q, *J* = 7.0 Hz, 2H), 2.41 (s, 3H), 1.33 (t, *J* = 8.0 Hz, 3H). ¹⁹F NMR (376 MHz, DMSO-*d*₆): δ - 117.6 (m). LCMS *m/z* found 326.1, calcd for C₁₉H₁₇FNO₃ [M+H]⁺ 326.1.

***N*-(4-Aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (14)** The title
5 acetamide compound was prepared from *N*-methyl-4-nitroaniline **11** using similar procedure as described in literature (Roth GJ, et al. J Med Chem. 2009;52(14):4466-4480). ¹H NMR (400 MHz, DMSO-*d*₆): δ 2.10 (s, 3H), 2.14–2.43 (m, 8H), 2.79 (s, 2H), 3.03 (s, 3H), 5.23 (s, 2H), 6.52–6.57 (m, 2H), 6.88–6.92 (m, 2H). HRMS *m/z* found 263.1866, calcd for C₁₄H₂₃N₄O [M+H]⁺ 263.1872.

**General procedure for the synthesis of final compounds 15–19. Methyl (Z)-3-(((4-*N*-
10 methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate (15).** To a suspension of methyl (Z)-1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate (**6**) (500 mg, 1.368 mmol) in DMF (3.5 mL) was added *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (**14**) (395 mg, 1.505 mmol, 1.1 equiv.) at room temperature. After heating the reaction mixture at 80 °C for 1 h,
15 it was allowed to cool to RT. Piperidine (297 μ L, 3.010 mmol, 2.2 equiv.) was then added and stirred for 2 h. Volatiles were removed *in vacuo* and water was added to the obtained residue and stirred for 15 min. Precipitate was then filtered under suction and cake was washed with water, then with minimum amount of cold methanol, and then ether. The obtained product was purified by column chromatography (neutral Al₂O₃, 0–10% methanol in CH₂Cl₂) to afford 532 mg (72%)
20 of target molecule **15**. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.22 (s, 1H), 10.98 (s, 1H), 7.66–7.47 (m, 5H), 7.42 (s, 1H), 7.24–7.09 (m, 3H), 6.89 (d, *J* = 8.0 Hz, 2H), 5.83 (d, *J* = 8.0 Hz, 1H), 3.77 (s, 3H), 3.06 (s, 3H), 2.69 (s, 2H), 2.34–2.06 (brs, 8H), 2.10 (s, 3H). HRMS *m/z* found 540.2606, calcd for C₃₁H₃₄N₅O₄ [M+H]⁺ 540.2605.

**(Z)-*N*-Methyl-2-(4-methylpiperazin-1-yl)-*N*-(4-(((2-oxoindolin-3-
25 ylidene)(phenyl)methyl)amino)phenyl)acetamide (16)** The title compound was synthesized in 64% yield using similar procedure as described for the synthesis of compound **15** by swapping (Z)-1-acetyl-3-(ethoxy(phenyl)methylene)indolin-2-one (**7**) for indolinone derivative **6**. A 58:42 mixture of conformers ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.19 and 12.02 (s, 1H), 10.74 and 10.59 (s, 1H), 7.61–5.75 (m, 13H), 3.17–2.64 (m, 5H), 2.36–2.07 (m, 11H). HRMS *m/z* found 482.2408,
30 calcd for C₂₉H₃₂N₅O₂ [M+H]⁺ 482.2400.

**Methyl(Z)-3-(((4-*N*-methyl-2-(4-methylpiperazin-1-
yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxylate (17).** The title
compound was synthesized in 73% yield using similar procedure as described for the synthesis of
compound **15** by swapping Methyl (Z)-1-acetyl-3-(ethoxy(phenyl)methylene)-2-oxoindoline-5-
35 carboxylate (**8**) for indolinone derivative **6**. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ

11.97 (s, 1H), 11.13 (s, 1H), 7.63–7.47 (m, 6H), 7.13 (d, $J = 8.4$ Hz, 2H), 6.94 (d, $J = 8.4$ Hz, 1H), 6.88 (d, $J = 8.4$ Hz, 2H), 6.51 (s, 1H), 3.63 (s, 3H), 3.06 (s, 3H), 2.69 (s, 2H), 2.19 (brs, 8H), 2.10 (s, 3H). HRMS m/z found 540.2613, calcd for $C_{31}H_{34}N_5O_4$ $[M+H]^+$ 540.2605.

(Z)-N-(4-(((5-Acetyl-2-oxoindolin-3-ylidene)(phenyl)methyl)amino)phenyl)-N-

5 **methyl-2-(4-methylpiperazin-1-yl)acetamide (18).** The title compound was synthesized in 63% yield using similar procedure as described for the synthesis of compound **15** by swapping (Z)-1,1'-(3-(Ethoxy(phenyl)methylene)-2-oxoindoline-1,5-diyl)bis(ethan-1-one) (**9**) for indolinone derivative **6**. Major conformer 1H NMR (400 MHz, DMSO- d_6): δ 11.94 (s, 1H), 11.14 (s, 1H), 7.63–7.50 (m, 6H), 7.13 (d, $J = 8.4$ Hz, 2H), 6.94 (d, $J = 8.4$ Hz, 1H), 6.90 (d, $J = 8.4$ Hz, 2H), 10 6.39 (s, 1H), 3.06 (s, 3H), 2.71 (s, 2H), 2.32–2.16 (brs, 8H), 2.14 (s, 6H). HRMS m/z found 523.2585, calcd for $C_{31}H_{33}N_5O_3$ $[M]^+$ 523.2583.

(Z)-N-(4-(((5-Fluoro-2-oxoindolin-3-ylidene)(phenyl)methyl)amino)phenyl)-N-

15 **methyl-2-(4-methylpiperazin-1-yl)acetamide (19).** The title compound was synthesized in 69% yield using similar procedure as described for the synthesis of compound **15** by swapping (Z)-1-acetyl-3-(Ethoxy(phenyl)methylene)-5-fluoroindolin-2-one (**10**) for indolinone derivative **6**. 1H NMR (400 MHz, DMSO- d_6): δ 12.09 (s, 1H), 10.76 (s, 1H), 7.63–7.48 (m, 5H), 7.12 (d, $J = 8.4$ Hz, 2H), 6.90–6.79 (m, 3H), 6.72 (m, 1H), 5.37 (dd, $J = 10.4$ Hz, 2.4 Hz, 1H), 3.05 (s, 3H), 2.67 (s, 2H), 2.18 (brs, 8H), 2.10 (s, 3H). ^{19}F NMR (376 MHz, DMSO- d_6): δ -123.3 (m). HRMS m/z found 500.2455, calcd for $C_{29}H_{31}FN_5O_2$ $[M+H]^+$ 500.2456.

20 **General procedure for the synthesis of final compounds 22–25.** (Z)-N-(3-(Dimethylamino)propyl)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxamide (**22**).

6-carboxylic acid methyl ester **15** (250 mg, 0.46 mmol) was added to 1:1 mixture of methanol and dioxane (8 mL). The resulting suspension was heated to 50 °C and then 1N aqueous NaOH solution 25 (2.5 mL) was added. The solution was stirred for 5h at 80 °C and then allowed to cool to room temperature. Volatiles were removed *in vacuo* and water was added to the obtained residue. After stirred for 10 minutes, the separated solids were filtered and washed with water and diethyl ether, and then dried under vacuum to afford crude (Z)-3-(((4-(N-Methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylic acid (**20**). Major 30 conformer 1H NMR (400 MHz, DMSO- d_6): δ 12.20 (s, 1H), 10.96 (s, 1H), 7.63–7.48 (m, 5H), 7.42 (s, 1H), 7.17 (dd, $J = 8.0$ Hz, 1.2 Hz, 1H), 7.13 (d, $J = 8.4$ Hz, 2H), 6.88 (d, $J = 8.0$ Hz, 2H), 5.81 (d, $J = 8.4$ Hz, 1H), 3.06 (s, 3H), 2.67 (s, 2H), 2.20 (brs, 8H), 2.12 (s, 3H). HRMS m/z found 525.2371, calcd for $C_{30}H_{31}N_5O_4$ $[M]^+$ 525.2376.

To a suspension of crude 6-carboxylic acid **20** (1.0 equiv.), HBTU or TBTU (1.2 equiv.), 35 HOBt (1.2 equiv.) in dimethylformamide was added DIPEA (16 equiv.) at room temperature. *N,N*-

dimethylpropane-1,3-diamine (1.5 equiv.) was then added and continued stirred for 2h. Volatiles were removed *in vacuo* and the obtained product was purified by column chromatography (neutral Al₂O₃, 0–10% methanol in CH₂Cl₂) or HPLC to afford the target molecule 2-oxoindoline-6-carboxamide **22**. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.10 (s, 1H), 10.93 (s, 1H), 8.24 (t, *J* = 5.2 Hz, 1H), 7.64–7.49 (m, 5H), 7.33 (d, *J* = 1.6 Hz, 1H), 7.12 (d, *J* = 8.4 Hz, 2H), 7.05 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 6.87 (d, *J* = 8.4 Hz, 2H), 5.74 (d, *J* = 8.0 Hz, 1H), 3.20 (q, *J* = 8.0 Hz, 2H), 3.05 (s, 3H), 2.69 (s, 2H), 2.33–2.05 (m, 19H), 1.59 (m, 2H). HRMS *m/z* found 610.3494, calcd for C₃₅H₄₄N₇O₃ [M+H]⁺ 610.3500.

(Z)-N-(3-Aminopropyl)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxamide (23). The title compound was synthesized using similar procedure as described for the synthesis of compound **22** by substituting *tert*-butyl (3-aminopropyl)carbamate for dimethylpropane-1,3-diamine followed by removal of Boc protecting with treatment of 20% TFA in dichloromethane at rt for 3 hr. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.15 (s, 1H), 10.98 (s, 1H), 8.37 (t, *J* = 5.2 Hz, 1H), 7.72–7.50 (m, 7H), 7.35 (s, 1H), 7.16 (d, *J* = 8.4 Hz, 2H), 7.08 (dd, *J* = 8.0 Hz, 1.6 Hz, 1H), 6.89 (d, *J* = 8.4 Hz, 2H), 5.74 (d, *J* = 8.4 Hz, 1H), 3.48–2.69 (m, 20H), 1.74 (m, 2H). HRMS *m/z* found 582.3186, calcd for C₃₃H₄₀N₇O₃ [M+H]⁺ 582.3187.

(Z)-N-Methyl-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxamide (24). **(Z)-3-(((4-(N-Methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxylic acid (21)** was synthesized using similar procedure as described for the synthesis of compound **20** by swapping indolinone **17** for indolinone derivative **15**. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.00 (s, 1H), 11.09 (s, 1H), 7.60–7.47 (m, 6H), 7.12 (d, *J* = 8.4 Hz, 2H), 6.92 (d, *J* = 8.0 Hz, 1H), 6.85 (d, *J* = 8.8 Hz, 2H), 6.59 (s, 1H), 3.05 (s, 3H), 2.69 (s, 2H), 2.19 (brs, 8H), 2.11 (s, 3H). HRMS *m/z* found 526.2453, calcd for C₃₀H₃₂N₅O₄ [M+H]⁺ 526.2449.

The title compound **24** was synthesized using similar procedure as described for the synthesis of compound **22** by substituting methylamine hydrochloride for dimethylpropane-1,3-diamine. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.03 (s, 1H), 10.97 (s, 1H), 7.93 (m, 1H), 7.62–7.46 (m, 5H), 7.39 (dd, *J* = 8.4 Hz, 1.6 Hz, 1H), 7.11 (d, *J* = 8.4 Hz, 2H), 6.85 (d, *J* = 8.4 Hz, 1H), 6.83 (d, *J* = 8.8 Hz, 2H), 6.53 (s, 1H), 3.05 (s, 3H), 2.69 (s, 2H), 2.63 (d, *J* = 4.8 Hz, 3H), 2.19 (brs, 8H), 2.11 (s, 3H). HRMS *m/z* found 539.2782, calcd for C₃₁H₃₅N₆O₃ [M+H]⁺ 539.2765.

(Z)-N,N-Dimethyl-3-(((4-(N-methyl-2-(4-methylpiperazin-1-

yl)acetamido)phenyl)amino)(phenyl)methylene)-2-oxoindoline-5-carboxamide (**25**). The title compound was synthesized using similar procedure as described for the synthesis of compound **22** by substituting dimethylamine hydrochloride for dimethylpropane-1,3-diamine. Major conformer ¹H NMR (400 MHz, DMSO-*d*₆): δ 12.03 (s, 1H), 10.94 (s, 1H), 7.62–7.48 (m, 5H), 7.11 (d, *J* = 8.4 Hz, 2H), 7.03 (dd, *J* = 8.0 Hz, 1.6 Hz, 1H), 6.88 (d, *J* = 8.0 Hz, 1H), 6.84 (d, *J* = 8.0 Hz, 2H), 5.86 (s, 1H), 3.05 (s, 3H), 2.76 (s, 6H), 2.69 (s, 2H), 2.18 (brs, 8H), 2.10 (s, 3H). HRMS *m/z* found 553.2930, calcd for C₃₂H₃₇N₆O₃ [M+H]⁺ 553.2922.

MELK assays and selectivity screening

10 Inhibitor library screening

MELK and its substrate, Bcl-G were both recombinantly expressed and purified for use in screening assays (See Methods). 752 compounds from an in-house curated inhibitor library were subjected to a p81-based kinase assay. 10 nM MELK 340 and 10 μM Bcl-G_L in kinase assay buffer (50 mM HEPES pH 7.5, 100 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 10 mM MgCl₂, 10 μg/mL BSA) with 10 mM DTT were added to either 10 μM or 1 μM inhibitor aliquoted into 96 well plates (final 1% DMSO). The mixture was incubated at room temperature for 30 minutes prior to initiation of the assay with 40 μM γ-³²P-ATP (100 – 1000 CPM/pmol). 40 μL aliquots were spotted onto a p81 96 well filter plate (Unifilter, Whatman), quenched, and washed with 75 mM O-phosphoric acid 8 times, followed by a final wash with acetone for drying. Wells were then filled with scintillation fluid, sealed, and quantified using a MicroBeta TriLux liquid scintillation counter (PerkinElmer). Each inhibitor plate was assayed in duplicate, with at least 4 wells without MELK to establish background and at least 4 wells without inhibitor as a negative control. All readings were corrected for background signal based on the average counts from the wells without enzyme. Percent inhibition, defined as [100 – (CPM + inhibitor/average CPM of positive controls)*100], was determined first at 10 μM inhibitor. The top 50 inhibitors were then re-screened in duplicate at 1 μM.

Characterization of hits and compound **15** (MELK-In-1) derivatives

The top 10 hits from the 1 μM screening and derivatives of MELK-In-1 were subjected to the same assay conditions with varied inhibitor concentrations (0.0005 – 50 μM) to generate a dose-response curve and IC₅₀. At set time points (0.25, 0.5, 1, 1.5, and 2 min for assays containing 10 nM MELK and 1, 2, 4, 6, and 10 min for assays containing 1 nM MELK), 30 μL aliquots were taken from each reaction and spotted onto 2 x 2 cm squares of p81 paper. Papers were washed 4 times in 75 mM O-phosphoric acid and once in acetone. Labeled protein was quantified by its

associated CPM determined on a Packard 1500 scintillation counter at a sigma value of 2. CPM were translated into nmol ³²P incorporated using Equation 1.

$$\text{Equation 1: } nmol P = \frac{(CPM/3)(1 \times 10^5)}{(1 \times 10^{-9}) \times \text{Specific Activity}}$$

5

Rates in the presence of each concentration of inhibitor were determined by plotting nmol ³²P incorporated vs. time. These rates were normalized to rates obtained without inhibitor, and data were plotted in terms of fractional activity. In most cases, data were fit to Equation 2. If the IC₅₀ approached the amount of enzyme used in the assay, data were re-fit to the equation for tight-binding inhibitors (the Morrison equation, Equation 2). To validate IC₅₀ values for MELK-In-7, 8, 9, and 11, assays were repeated in the presence of 1 nM enzyme instead of 10 nM. Data were transformed as discussed and fit to Equation 3.

$$\text{Equation 2: } \frac{v_i}{v_0} = 1 - \frac{[I]}{([I] + IC_{50})}$$

where v_i is the observed rate with inhibitor, v_0 is the rate in the absence of inhibitor, $[I]$ is inhibitor concentration in nM, and IC_{50} is the concentration of inhibitor at which half maximal change in v_0 is observed.

$$\text{Equation 3: } \frac{v_i}{v_0} = 1 - \frac{(E_T + [I] + IC_{50}) - \sqrt{(E_T + [I] + IC_{50})^2 - 4E_T[I]}}{2E_T}$$

where E_T was constrained to the total enzyme in the assay.

IC₅₀ values were used to estimate each inhibitor's K_i using the Cheng-Prusoff relationship for competitive inhibitors (Equation 4). Apparent K_M^{ATP} for MELK was experimentally determined for screening and derivative conditions by performing two independent dose-response curves with varied ATP (0 – 1.28 mM). The value obtained, $K_M^{ATP} = 6 \pm 1.5 \mu\text{M}$, was used as a parameter in Equation 4 in the course of fitting the K_i .

$$\text{Equation 4: } K_i = IC_{50} / \left(1 + \frac{[ATP]}{K_M^{ATP}} \right)$$

25

Selectivity screening

Candidates for inhibitor selectivity characterization were chosen based on an initial single-timepoint commercial kinome profiling screen performed with inhibitor **17** (MELK-In-7) (KinomeScan, DiscoverRx, San Diego, CA), primary sequence relation to MELK, and laboratory availability. CHK1 and NUA1 were purchased from SignalChem (Vancouver, BC). The NUA2, CHK, and SAMS peptides were purchased from BioSyn (Lewisville, TX). The sequence of CHK and NUA2 peptides are described elsewhere (Sanchez Y, et al. Science (New York,

30

N.Y.). 1997;277(5331):1497-1501; Scott JW, et al. *Sci Rep.* 2015;5:14436). ERK2, AMPK, CAMKK2, and Ets1 were produced in house as previously described (Waas WF, Dalby KN. *The Journal of biological chemistry.* 2002;277(15):12532-12540; Neumann D, et al. *Protein Expr Purif.* 2003;30(2):230-237; Waas WF, Dalby KN. *Protein Expr Purif.* 2001;23(1):191-197).

5 Apparent K_M values for ATP under specific assay conditions were determined using respective experimental conditions in Table 8 with varied ATP (0 – 1.28 mM). All selectivity dose-response assays were performed in kinase assay buffer (see Inhibitor Library Screen) with 2 mM DTT and 100 μ M γ -³²P-ATP with additional conditions listed in Table 8. IC_{50} and K_M^{ATP} values were subsequently used to calculate K_i (Equation 4). Relative selectivity was determined by comparing
10 $K_i^{Enzyme} / K_i^{MELK}$ (termed ϕ in Table 7). All IC_{50} and/or K_i data were fit using Prism® (GraphPad) using equations 2, 3, and 4, as appropriate. Standard error from linear regression data was propagated internally in Prism and taken into account in nonlinear regression to determine IC_{50} or K_i .

15 Cell culture and reagents

HCC70, BT-549, and SUM159 human TNBC cell lines and MCF10A human breast epithelial cell line were purchased from American Type Culture Collection. The murine 4T1-Luc TNBC cells were purchased from PerkinElmer. HCC70, BT-549, and 4T1-Luc cells were maintained in RPMI 1640 medium (Life Technologies Inc., Grand Island, NY, USA) and MDA-
20 MB-231-LM2 cells in Dulbecco's modified Eagle's medium/F12 medium (Life Technologies Inc., Grand Island, NY, USA), both types of medium supplemented with FBS (10%) and antibiotic/antimycotic (1%). SUM159 cells were maintained in Ham's F-12 medium (Life Technologies Inc., Grand Island, NY, USA) supplemented with FBS (5%), antibiotic/antimycotic (1%), insulin (5 μ g/mL), and hydrocortisone (1 μ g/mL). MCF10A cells were maintained in
25 Dulbecco's modified Eagle's medium/F12 medium supplemented with horse serum (10%), antibiotic/antimycotic (1%), insulin (10 μ g/mL), EGF (20 ng/mL), cholera toxin (100 ng/mL), and hydrocortisone (500 μ g/mL). All cell lines used in this study were validated by the Characterized Cell Line Core Facility at MD Anderson Cancer Center by using a short tandem repeat method based on primer extension to detect single base deviations.

30

Western blotting

Western blotting was done as described previously (Bartholomeusz C, et al. *Clinical cancer research: an official journal of the American Association for Cancer Research.* 2010;16(6):1802-
35 1811). Proteins of interest were probed using the following primary antibodies (1:1000 dilution)

purchased from Cell Signaling Technology (Danvers, MA, USA) or other suppliers as indicated: anti-fibronectin (1:500 dilution; BD Transduction), anti-vimentin, anti-E-cadherin (1:1000 dilution; BD Transduction), anti- β -catenin, anti-snail (1:1000 dilution; Santa Cruz), and anti- α -tubulin (clone DM1A, T9026, Sigma-Aldrich, St. Louis, MO, USA). Secondary antibodies were
5 horseradish peroxidase-conjugated IgG (1:10,000 dilution; Invitrogen) for chemiluminescent signal detection and the corresponding Alexa Fluor-conjugated IgG (1:5000 dilution; Invitrogen) for fluorescence signal detection.

Cell proliferation assay

10 Cell proliferation was determined using the CellTiter-Blue viability assay as described previously (Gloeckner H, et al. Journal of immunological methods. 2001;252(1-2):131-138). Cells were seeded in 96-well plates and treated the next day with MELK inhibitors (0-20 μ M). At 72 h after MELK inhibitor treatment, optical density at 595 nm was determined.

15 Cloning and recombinant expression of MELK and Bcl-G

The plasmid containing full length MELK (GenBank Accession number NM_014791) was a generous gift of Dr. Garth Powis (Sanford Burnham Prebys). The catalytic domain of MELK (amino acids 1-340) was subcloned into pET28a using the NdeI/XhoI restriction sites. Insertion and sequence were verified by DNA sequencing. Plasmids were transformed into BL21(DE3) *E.*
20 *coli*, grown in TB media to an OD₅₉₅ of 0.6, and induced with 0.5 mM IPTG. Cultures were grown for 5 hours at 25°C, harvested by centrifugation at 15,000 rpm at 4°C for 30 minutes, and flash frozen for storage at -80°C. Pellets were resuspended in Ni-NTA lysis buffer (20 mM Tris pH 8, 0.5 M NaCl, 0.03% Brij-35, 1% Triton X-100, 5 mM imidazole, 1 mM benzamidine, 0.1 mM TPCK, 0.1 mM PMSF, and 0.1% β -mercaptoethanol) and sonicated. Lysates were cleared by
25 centrifugation and supernatants incubated with nickel beads (Qiagen) at 4°C for 1 hour. Beads were washed (20 mM Tris pH 8, 0.03% Brij-35, 10 mM imidazole, 1 mM benzamidine, 0.1 mM TPCK, 0.1 mM PMSF, and 0.1% β -mercaptoethanol) and hexahistidine-tagged MELK was subsequently eluted (20 mM Tris pH 8, 0.03% Brij-35, 250 mM imidazole, 1 mM benzamidine, 0.1 mM TPCK, 0.1 mM PMSF, and 0.1% β -mercaptoethanol). Nickel eluates were subsequently
30 dialyzed into equilibration buffer (20 mM Tris pH 8, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% β -mercaptoethanol), loaded onto an anion exchange column (MonoQ 10/100, GE Healthcare), and eluted over a 17 column volume linear gradient of 0 – 0.5 M NaCl. Fractions were analyzed by SDS-PAGE. Protein was dialyzed into storage buffer (25 mM HEPES pH 7.5, 50 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 2 mM DTT, 10% glycerol) and stored at -80°C.

Full-length cDNA for Bcl-G_L (GenBank Accession number BC025778) was purchased from Open Biosystems and subcloned into pET28a using LIC. After insertion and sequence verification, plasmids were transformed into BL21(DE3) E. coli, cultured in TB media to an OD₅₉₅ of 0.6, and induced with 50 μM IPTG. Flasks were incubated overnight (18 hours) at 18°C and
5 harvested and purified using nickel affinity and anion exchange columns as described for MELK.

Table 8. Conditions used in selectivity screening.

Enzyme	Conditions	Time Course	Apparent $K_M^{ATP} \pm SE$ (μM)
AMPK	10 nM AMPK, 100 μM SAMS, 50 μM AMP	0.25 – 2 min	98 ± 8.4
CAMKK2	50 nM CAMKK2, 200 μM NUAK2 peptide, 150 μM total Ca ²⁺ , 1 μM calmodulin	0.5 – 6 min	265 ± 25
CHK1	5 nM CHK1, 100 μM CHK peptide	0.25 – 4 min	125 ± 2.5
ERK2	1 nM ERK2, 20 μM Ets-1	0.25 – 4 min	98 ± 14
NUAK1	10 nM NUAK1, 100 μM CHK peptide	0.25 – 4 min	60 ± 3.6

References cited in this example

- 10 The disclosures of all articles and references, including patent applications and publications, are incorporated by reference for all purposes.
1. Gil M, et al. *Gene*. 1997;195(2):295-301.
 2. Beullens M, et al. *The Journal of biological chemistry*. 2005;280(48):40003-40011.
 3. Blot J, et al. *Dev Biol*. 2002;241(2):327-338.
 - 15 4. Davezac N, et al. *Oncogene*. 2002;21(50):7630-7641.
 5. Joshi K, et al. *Stem cells (Dayton, Ohio)*. 2013.
 6. Saito R, et al. *Cancer science*. 2012;103(1):42-49.
 7. Lin ML, et al. *Breast cancer research : BCR*. 2007;9(1):R17.
 8. Pickard MR, et al. *Biochimica et biophysica acta*. 2011;1812(9):1146-1153.
 - 20 9. Vulsteke V, et al. *The Journal of biological chemistry*. 2004;279(10):8642-8647.
 10. Heyer BS, et al. *Molecular reproduction and development*. 1997;47(2):148-156.

11. Wang Y, et al. *eLife*. 2014:e01763.
12. Nakano I, et al. *The Journal of cell biology*. 2005;170(3):413-427.
13. Niesler CU, et al. *Experimental physiology*. 2007;92(1):207-217.
14. Hebbard LW, et al. *Cancer research*. 2010;70(21):8863-8873.
- 5 15. Nakano I, et al. *Neuro-oncology*. 2011;13(6):622-634.
16. Nakano I, et al. *Journal of neuroscience research*. 2008;86(1):48-60.
17. Gray D, et al. *Cancer research*. 2005;65(21):9751-9761.
18. Ryu B, et al. *PloS one*. 2007;2(7):e594.
19. Marie SK, et al. *International journal of cancer. Journal international du cancer*.
10 2008;122(4):807-815.
20. Li Y, et al. *Lung cancer (Amsterdam, Netherlands)*. 2013.
21. Rajkumar T, et al. *BMC cancer*. 2011;11:80.
22. Risinger JI, et al. *Frontiers in oncology*. 2013;3:139.
23. Kappadakunnel M, et al. *Journal of neuro-oncology*. 2010;96(3):359-367.
- 15 24. Komatsu M, et al. *International journal of oncology*. 2013;42(2):478-506.
25. Al-Ejeh F, et al. *Oncogenesis*. 2014;3:e100.
26. Marie SK, et al. *Proteome Sci*. 2016;14:6.
27. Seong HA, et al. *The Journal of biological chemistry*. 2010;285(40):30959-30970.
28. Miduturu CV, et al. *Chemistry & biology*. 2011;18(7):868-879.
- 20 29. Uitdehaag JC, et al. *Br J Pharmacol*. 2012;166(3):858-876.
30. Mathea S, et al. *ACS Chem Biol*. 2016;11(6):1595-1602.
31. Elkins JM, et al. *Nat Biotechnol*. 2016;34(1):95-103.
32. Prakash CR, et al. *Mini reviews in medicinal chemistry*. 2012;12(2):98-119.
33. Aronov AM, et al. *Journal of medicinal chemistry*. 2008;51(5):1214-1222.
- 25 34. Canevari G, et al. *Biochemistry*. 2013;52(37):6380-6387.
35. Toure BB, et al. *J Med Chem*. 2016;59(10):4711-4723.
36. Furtmann N, et al. *J Med Chem*. 2015;58(1):252-264.
37. Roth GJ, et al. *J Med Chem*. 2009;52(14):4466-4480.
38. Zhao B, et al. *The Journal of biological chemistry*. 2002;277(48):46609-46615.
- 30 39. Beke L, et al. *Biosci Rep*. 2015.
40. Lehmann BD, et al. *The Journal of clinical investigation*. 2011;121(7):2750-2767.
41. Kao J, et al. *PloS one*. 2009;4(7):e6146.
42. Heckel AB, et al. Inventor; Boehringer Ingelheim International GmbH (Ingelheim, DE),
assignee. Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use
35 as medicaments. 2007.


43. Sanchez Y, et al. *Science (New York, N.Y.)*. 1997;277(5331):1497-1501.
44. Scott JW, et al. *Sci Rep*. 2015;5:14436.
45. Waas WF, Dalby KN. *The Journal of biological chemistry*. 2002;277(15):12532-12540.
46. Neumann D, et al. *Protein Expr Purif*. 2003;30(2):230-237.
- 5 47. Waas WF, Dalby KN. *Protein Expr Purif*. 2001;23(1):191-197.
48. Bartholomeusz C, et al. *Clinical cancer research : an official journal of the American Association for Cancer Research*. 2010;16(6):1802-1811.
49. Gloeckner H, et al. *Journal of immunological methods*. 2001;252(1-2):131-138.

10

Example 2. Synthesis of indolinone derivatives 91-108


A number of indolinone derivatives were synthesized in order to improve potency and selectivity. (See Compounds 91-108). The general synthetic routes are outlined in Schemes 3 and 4. The key intermediates 79-90 were prepared via modified Bischler-napieralski reactions of 2-
15 alkynylaryl isocyanates 67-78 with iron trichloride (Cantagrel, G., et al. *J. Org. Lett.*, 2009, 11, 4262-4265).

20



Scheme 3.

Synthesis of intermediate. Reagents and conditions: (k) PdCl₂(PPh₃)₂, CuI, TEA, toluene, rt, overnight, 65% – quant.; (l) TBAF, THF, rt, 2h, 98 % – quant.; (m) PdCl₂(PPh₃)₂, CuI, TEA, THF, rt, overnight, 85% – quant.; (n) imidazole, DMF, rt, overnight, (o) acetic anhydride, DCM, rt, 6h, 84%.



Scheme 4.


Synthesis of intermediate. Reagents and conditions: (p) triphosgene, TEA, toluene, rt, 3h; (q) FeCl₃, DCM, rt, overnight, 19 % – quant. (two steps from p and q); (r) ethanol, reflux, overnight, 34% – quant.; (s) SnCl₂, ethanol, 70 °C, overnight, 76% - quant.; (i) 1N aq. NaOH, methanol/1,4-dioxane, 80 °C, 6h, 80 – 96%.

Stereoselectively converted final indolinone (*Z*)-3- (aminoarylmethylene)oxindoles analogs were synthesized by addition of compound 14 to 3-(arylchloromethylene)oxindoles 79-90. which can be subsequently stereoselectively converted to (*Z*)-3- (aminoarylmethylene)oxindoles (scheme 4). Additional amino analogs 111 and 112 were prepared from the corresponding nitro derivatives 99 and 101 through reduction by tin (II) chloride. Alcohol

analogues 113 and 114 were also obtained via TBS-deprotection using TBAF. 5-acid derivatives 107-108 were synthesized through hydrolysis using aqueous 1N NaOH (Scheme 4).

Methyl 4-amino-3-((trimethylsilyl)ethynyl)benzoate (**27**)

5




A combined suspension of methyl 4-amino-3-((trimethylsilyl)ethynyl)benzoate (1.50 g, 5.41 mmol), copper (I) iodide (21 mg, 0.11 mmol), bis(triphenylphosphine)palladium(II) dichloride (76 mg, 0.11 mmol), and ethynyltrimethylsilane (0.90 mL, 6.50 mmol) were stirred in 10 toluene and TEA (1/1, 46 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **27** as a white solid (1.33 g, 99% yield):

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 8.00 (d, $J = 2.0$ Hz, 1H), 7.77 (dd, $J = 8.6, 2.0$ Hz, 1H), 6.65 (d, $J = 8.5$ Hz, 1H), 4.69 (bs, 2H), 3.83 (s, 3H), 0.26 (s, 9H);

15 $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 166.6, 152.0, 134.7, 131.7, 119.2, 113.2, 107.0, 100.6, 100.6, 51.8, 0.2.

Methyl 4-amino-3-ethynylbenzoate (**28**)

20




To a solution of methyl 4-amino-3-((trimethylsilyl)ethynyl)benzoate (1.34 g, 5.42 mmol) in THF (11 mL) was added tetrabutylammonium fluoride solution (5.96 ml, 1M in THF). After 25 addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (20 ml). Water (15 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 , and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography,

by column chromatography with hexane/ethyl acetate (2/1, v/v) to obtain the compound **28** as a white solid (949 mg, quant. yield):

^1H NMR (400 MHz, CDCl_3) δ 8.01 (d, $J = 2.0$ Hz, 1H), 7.79 (dd, $J = 8.6, 2.0$ Hz, 1H), 6.65 (d, $J = 8.6$ Hz, 1H), 4.74 (bs, 2H), 3.83 (s, 3H), 3.39 (s, 1H);

5 ^{13}C NMR (100 MHz, CDCl_3) δ 166.6, 152.3, 134.9, 131.9, 119.1, 113.3, 105.8, 83.1, 76.8, 51.8, 29.8.

Methyl 4-amino-3-((4-nitrophenyl)ethynyl)benzoate (**31**)




10

A suspension of methyl 4-amino-3-ethynylbenzoate (1.01 g, 5.78 mmol), 1-bromo-4-nitrobenzene (1.40 g, 6.93 mmol), copper (I) iodide (55 mg, 0.29 mmol), bis(triphenylphosphine)palladium(II) dichloride (203 mg, 0.29 mmol), TEA (2.42 ml, 1.73 mmol) were stirred in THF (10 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (1/1, v/v) to obtain the compound **31** as a yellow solid (1.71 g, quant. yield):

15 ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.27 (d, $J = 8.3$ Hz, 2H), 7.95 (d, $J = 8.3$ Hz, 2H), 7.89 (d, $J = 2.1$ Hz, 1H), 7.70 (dd, $J = 8.7, 2.1$ Hz, 1H), 6.78 (d, $J = 8.3$ Hz, 1H), 6.60 (bs, 2H), 3.77 (s, 3H).

20

Methyl 4-amino-3-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (**32**)



25


A suspension of methyl 4-amino-3-ethynylbenzoate (2.04 g, 11.65 mmol), methyl 4-bromobenzoate (3.01 g, 13.97 mmol), copper (I) iodide (111 mg, 0.58 mmol), bis(triphenylphosphine)palladium(II) dichloride (409 mg, 0.58 mmol), TEA (4.87 ml, 34.93 mmol) were stirred in THF (19 mL) at ambient temperature for overnight. The reaction solvent

was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (1/1, v/v) to obtain the compound **32** as a brown solid (3.05 g, 85% yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 87.98 (d, *J* = 8.1 Hz, 2H), 7.86 (d, *J* = 2.1 Hz, 1H), 7.81 (d, *J* = 8.7 Hz, 2H), 7.68 (dd, *J* = 8.7, 2.1 Hz, 1H), 6.77 (d, *J* = 8.7 Hz, 1H), 6.50 (s, 2H), 3.87 (s, 3H), 3.77 (s, 3H);

¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.7, 165.6, 153.8, 134.3, 131.6, 131.5, 129.2, 128.8, 127.6, 116.3, 113.4, 104.1, 93.4, 88.9, 52.3, 51.5.

10 Trimethyl((3-nitrophenyl)ethynyl)silane (**39**)




A suspension of 1-iodo-3-nitrobenzene (3.00 g, 12.05 mmol), ethynyltrimethylsilane (2.00 mL, 14.46 mmol), copper (I) iodide (115 mg, 0.60 mmol), bis(triphenylphosphine)palladium(II) dichloride (423 mg, 0.60 mmol), TEA (5.04 ml, 36.14 mmol) were stirred in THF (20 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (10/1, v/v) to obtain the compound **39** (2.64 g, quant. yield):

¹H NMR (400 MHz, CDCl₃) δ 8.31 (t, *J* = 2.0 Hz, 1H), 8.16 (dd, *J* = 8.3, 1.1 Hz, 1H), 7.75 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.49 (t, *J* = 8.0 Hz, 1H), 0.27 (s, 9H);

¹³C NMR (100 MHz, CDCl₃) δ 137.7, 129.4, 126.9, 125.1, 123.3, 102.3, 97.8, -0.1.

(Benzo[*d*][1,3]dioxol-5-ylethynyl)trimethylsilane (**40**)



25


A suspension of 5-iodobenzo[*d*][1,3]dioxole (3.00 g, 12.10 mmol), ethynyltrimethylsilane (2.01 mL, 14.52 mmol), copper (I) iodide (115 mg, 0.61 mmol), bis(triphenylphosphine)palladium(II)

dichloride (424 mg, 0.61 mmol), TEA (5.06 ml, 36.29 mmol) were stirred in THF (20 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (10/1, v/v) to obtain the compound **40** (2.64 g, quant. yield):

- 5 ^1H NMR (400 MHz, CDCl_3) δ 6.98 (dd, $J = 8.1, 1.6$ Hz, 1H), 6.89 (d, $J = 1.6$ Hz, 1H), 6.70 (d, $J = 8.0$ Hz, 1H), 5.92 (s, 2H), 0.23 (s, 9H);
 ^{13}C NMR (100 MHz, CDCl_3) δ 148.1, 147.4, 126.8, 116.5, 111.9, 108.4, 105.1, 101.4, 92.3, 0.1.

1-Ethynyl-3-nitrobenzene (**41**)

10




To a solution of trimethyl((3-nitrophenyl)ethynyl)silane (4.24 g, 19.34 mmol) in THF (39 mL) was added tetrabutylammonium fluoride solution (21.27 ml, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (20 ml). Water (15 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 , and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (20/1, v/v) to obtain the compound **41** as a yellow solid (1.77 mg, quant. yield):

- 15 ^1H NMR (400 MHz, CDCl_3) δ 8.31 (t, $J = 1.9$ Hz, 1H), 8.20 (dd, $J = 8.3, 1.1$ Hz, 1H), 7.79 (dt, $J = 7.7, 1.3$ Hz, 1H), 7.53 (t, $J = 8.0$ Hz, 1H), 3.24 (s, 1H);
20 ^{13}C NMR (100 MHz, CDCl_3) δ 137.9, 129.5, 127.0, 124.0, 123.6, 81.2, 80.0.

25

5-Ethynylbenzo[*d*][1,3]dioxole (**42**)




To a solution of (benzo[*d*][1,3]dioxol-5-ylethynyl)trimethylsilane (3.77 g, 17.27 mmol) in THF (35 mL) was added tetrabutylammonium fluoride solution (19.00 mL, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (20 mL). Water (15 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (20/1, v/v) to obtain the compound **42** as a brown solid (1.74 mg, 98% yield):

- ¹H NMR (400 MHz, CDCl₃) δ 7.00 (dd, *J* = 8.0, 1.6 Hz, 1H), 6.91 (d, *J* = 1.6 Hz, 1H), 6.71 (d, *J* = 8.0 Hz, 1H), 5.92 (s, 2H), 2.98 (s, 1H);
¹³C NMR (100 MHz, CDCl₃) δ 148.3, 147.4, 126.8, 115.2, 112.0, 108.4, 101.4, 83.6, 75.7.

Methyl 4-amino-3-((3-nitrophenyl)ethynyl)benzoate (**43**)

15




A combined suspension of methyl 4-amino-3-iodobenzoate (2.78 g, 10.04 mmol), copper (I) iodide (38 mg, 0.20 mmol), bis(triphenylphosphine)palladium(II) dichloride (141 mg, 0.20 mmol), and 1-ethynyl-3-nitrobenzene (1.77 g, 12.05 mmol) were stirred in toluene and TEA (1/1, 54 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (3/1, v/v) to obtain the compound **43** as a yellow solid (2.33 g, 78% yield):

- ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.62 (t, *J* = 1.9 Hz, 1H), 8.22 (dd, *J* = 8.3, 1.1 Hz, 1H), 8.08 (dt, *J* = 7.7, 1.3 Hz, 1H), 7.90 (d, *J* = 2.3 Hz, 1H), 7.70 (q, *J* = 8.0 Hz, 1H), 7.69 (d, *J* = 8.7 Hz, 1H), 6.77 (d, *J* = 8.7 Hz, 1H), 6.60 (s, 2H), 3.77 (s, 3H);
¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.6, 153.7, 147.9, 137.5, 134.4, 131.6, 130.1, 125.9, 124.4, 123.0, 116.2, 113.4, 103.8, 91.9, 88.1, 51.5.

30

Methyl 4-amino-3-(*p*-tolylethynyl)benzoate (**44**)




5 A combined suspension of methyl 4-amino-3-iodobenzoate (2.50 g, 9.02 mmol), copper (I) iodide (35 mg, 0.18 mmol), bis(triphenylphosphine)palladium(II) dichloride (127 mg, 0.18 mmol), and 1-ethynyl-4-methylbenzene (1.37 mL, 10.83 mmol) were stirred in toluene and TEA (1/1, 76 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **44** as a white solid (2.39 g, quant. yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.81 (d, *J* = 2.0 Hz, 1H), 7.65 (dd, *J* = 8.7, 2.1 Hz, 1H), 7.56 – 53 (m, 2H), 7.24 – 7.21 (m, 2H), 6.76 (d, *J* = 8.7 Hz, 1H), 6.36 (s, 2H), 3.75 (s, 3H), 2.33 (s, 3H); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.7, 153.4, 138.2, 133.8, 131.4, 131.0, 129.2, 119.6, 116.2, 113.2, 105.1, 94.4, 84.9, 51.5, 21.1.

15

Methyl 4-amino-3-((4-ethylphenyl)ethynyl)benzoate (**45**)




20 A combined suspension of methyl 4-amino-3-iodobenzoate (2.0 g, 7.22 mmol), copper (I) iodide (28 mg, 0.14 mmol), bis(triphenylphosphine)palladium(II) dichloride (101 mg, 0.14 mmol), and 1-ethyl-4-ethynylbenzene (1.22 mL, 8.66 mmol) were stirred in toluene and TEA (1/1, 60 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **45** as a white solid (2.02 g, quant. yield):

¹H NMR (400 MHz, CDCl₃) δ 8.07 (d, *J* = 2.0 Hz, 1H), 7.78 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.41 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.2 Hz, 2H), 6.64 (d, *J* = 8.6 Hz, 1H), 4.86 (s, 2H), 3.81 (s, 3H), 2.6 (q, *J* = 7.6 Hz, 2H), 1.19 (t, *J* = 7.6 Hz, 3H);

^{13}C NMR (100 MHz, CDCl_3) δ 166.6, 151.7, 144.8, 134.1, 131.3, 131.1, 127.9, 119.8, 118.8, 113.1, 107.1, 95.2, 84.1, 51.6, 28.7, 15.2.

Methyl 4-amino-3-((4-methoxyphenyl)ethynyl)benzoate (**46**)

5



A combined suspension of methyl 4-amino-3-iodobenzoate (3.0 g, 10.83 mmol), copper (I) iodide (41 mg, 0.22 mmol), bis(triphenylphosphine)palladium(II) dichloride (152 mg, 0.22

10

mmol), and 1-ethynyl-4-methoxybenzene (1.69 mL, 12.99 mmol) were stirred in toluene and TEA (1/1, 90 mL) at ambient temperature for overnight. The reaction solvent was evaporated

under reduced pressure, and the residue was purified by column chromatography with

hexane/ethyl acetate (3/1, v/v) to obtain the compound **46** as a white solid (2.96 g, 97% yield):


15

^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, $J = 2.1$ Hz, 1H), 7.77 (dd, $J = 8.6, 2.1$ Hz, 1H), 7.41 (d, $J = 8.4$ Hz, 2H), 6.82 (d, $J = 8.4$ Hz, 2H), 6.65 (d, $J = 8.6$ Hz, 1H), 4.88 (s, 2H), 3.82 (s, 3H), 3.73 (s, 3H);

^{13}C NMR (101 MHz, CDCl_3) δ 166.6, 159.6, 151.6, 134.0, 132.8, 131.0, 118.8, 114.7, 113.9, 113.1, 107.2, 95.0, 83.4, 55.1, 51.6.

20

Methyl 4-amino-3-((3-methoxyphenyl)ethynyl)benzoate (**47**)



25

A combined suspension of methyl 4-amino-3-iodobenzoate (3.0 g, 10.83 mmol), copper (I) iodide (41 mg, 0.22 mmol), bis(triphenylphosphine)palladium(II) dichloride (152 mg, 0.22 mmol), and 1-ethynyl-3-methoxybenzene (1.69 mL, 12.99 mmol) were stirred in toluene and TEA (1/1, 90 mL) at ambient temperature for overnight. The reaction solvent was evaporated under

reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (3/1, v/v) to obtain the compound **47** as a white solid (3.00 g, 98% yield):


^1H NMR (400 MHz, CDCl_3) δ 8.07 (d, $J = 2.1$ Hz, 1H), 7.78 (dd, $J = 8.2, 2.0$ Hz, 1H), 7.21 (t, $J = 7.9$ Hz, 1H), 7.08 (dt, $J = 7.7, 1.2$ Hz, 2H), 7.03 – 7.02 (m, 2H), 6.87 – 6.86 (m, 1H), 6.66 (d, $J =$

5 8.6 Hz, 1H), 4.90 (s, 2H), 3.82 (s, 3H), 3.74 (s, 3H);

^{13}C NMR (100 MHz, CDCl_3) δ 166.5, 159.2, 151.7, 134.3, 131.3, 129.4, 123.8, 123.7, 118.8, 116.2, 114.8, 113.2, 106.7, 94.9, 84.6, 55.1, 51.6.

Methyl 4-amino-3-(benzo[*d*][1,3]dioxol-5-ylethynyl)benzoate (**48**)

10



A combined suspension of methyl 4-amino-3-iodobenzoate (2.74 g, 9.90 mmol), copper (I) iodide (38 mg, 1.98 mmol), bis(triphenylphosphine)palladium(II) dichloride (139 mg, 1.98

15


mmol), and 5-ethynylbenzo[*d*][1,3]dioxole (1.74 g, 11.89 mmol) were stirred in toluene and TEA (1/1, 82 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (3/1, v/v) to obtain the compound **48** as a white solid (2.92 g, quant. yield):

^1H NMR (400 MHz, CDCl_3) δ 8.04 (d, $J = 2.0$ Hz, 1H), 7.78 (dd, $J = 8.6, 2.0$ Hz, 1H), 7.03 (dd, $J = 8.0, 1.6$ Hz, 1H), 6.94 (d, $J = 1.6$ Hz, 1H), 6.77 (d, $J = 8.0$ Hz, 1H), 6.67 (d, $J = 8.6$ Hz, 1H), 5.97 (s, 2H), 4.74 (bs, 2H), 3.85 (s, 3H);

20

^{13}C NMR (100 MHz, CDCl_3) δ 166.7, 151.5, 148.1, 147.5, 134.3, 131.3, 126.2, 119.3, 116.1, 113.3, 111.4, 108.6, 107.2, 101.5, 95.1, 83.2, 51.8.

25 4-((Trimethylsilyl)ethynyl)phenol (**52**)




A suspension of 4-iodophenol (3.00 g, 13.64 mmol), ethynyltrimethylsilane (2.27 mL, 16.36 mmol), copper (I) iodide (130 mg, 0.68 mmol), bis(triphenylphosphine)palladium(II) dichloride (479 mg, 0.68 mmol), TEA (5.70 ml, 40.91 mmol) were stirred in THF (23 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (2/1, v/v) to obtain the compound **52** (1.76 g, 68% yield):

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.33 (d, $J = 8.7$ Hz, 2H), 6.72 (d, $J = 8.7$ Hz, 2H), 5.82 (bs, 1H), 0.23 (s, 9H);

$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 155.8, 133.8, 115.6, 115.4, 105.6, 92.9, 0.1.

10

(4-((Trimethylsilyl)ethynyl)phenyl)methanol (**53**)



15

A suspension of (4-iodophenyl)methanol (3.00 g, 13.64 mmol), ethynyltrimethylsilane (2.13 mL, 15.38 mmol), copper (I) iodide (122 mg, 0.64 mmol), bis(triphenylphosphine)palladium(II) dichloride (450 mg, 0.64 mmol), TEA (5.36 ml, 38.46 mmol) were stirred in THF (22 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (20/1, v/v) to obtain the compound **53** (2.66 g, quant. yield):


20

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.44 (d, $J = 8.4$ Hz, 2H), 7.26 (d, $J = 8.5$ Hz, 2H), 4.63 (s, 2H), 2.17 (bs, 1H), 0.25 (s, 9H);

$^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 141.3, 132.2, 126.7, 122.4, 105.0, 94.3, 64.9, 0.1.

25

2-(4-((Trimethylsilyl)ethynyl)phenyl)ethan-1-ol (**54**)



30


A suspension of (4-iodophenyl)ethanol (3.00 g, 12.09 mmol), ethynyltrimethylsilane (2.01 mL, 14.51 mmol), copper (I) iodide (115 mg, 0.60 mmol), bis(triphenylphosphine)palladium(II)

dichloride (424 mg, 0.60 mmol), TEA (5.06 ml, 36.28 mmol) were stirred in THF (20 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **54** (2.64 g, quant. yield):

- 5 $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.38 (d, $J = 8.3$ Hz, 2H), 7.08 (d, $J = 8.2$ Hz, 2H), 3.66 (td, $J = 7.0$, 3.9 Hz, 2H), 2.72 (t, $J = 6.8$ Hz, 2H), 0.25 (s, 9H);
 $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 139.4, 132.0, 128.9, 121.0, 105.1, 93.7, 63.0, 38.9, 0.01.

4-Ethynylphenol (**55**)

10




To a solution of 4-((trimethylsilyl)ethynyl)phenol (1.76 g, 9.25 mmol) in THF (19 mL) was added tetrabutylammonium fluoride solution (10.17 ml, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (20 ml). Water (15 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 , and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **55** as a white solid (511 mg, 47% yield):

- 15 $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 7.39 (d, $J = 8.7$ Hz, 2H), 6.78 (d, $J = 8.7$ Hz, 2H), 5.21 (bs, 1H), 3.00 (s, 1H);
 $^{13}\text{C NMR}$ (100 MHz, CDCl_3) δ 156.1, 134.0, 115.6, 114.5, 83.7, 76.0.

25

(4-Ethynylphenyl)methanol (**56**)



30 To a solution of 4-((trimethylsilyl)ethynyl)phenyl)methanol (2.96 g, 14.47 mmol) in THF (29 mL) was added tetrabutylammonium fluoride solution (15.92 ml, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under


reduced pressure, and the residue was dissolved in DCM (20 ml). Water (15 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (3/1, v/v) to obtain the compound **56** as a white solid (1.66 mg, 87% yield):

¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.3 Hz, 2H), 7.17 (d, *J* = 8.6 Hz, 2H), 4.48 (s, 2H), 3.59 (s, 1H), 3.09 (s, 1H);

¹³C NMR (100 MHz, CDCl₃) δ 141.5, 132.2, 126.7, 121.0, 83.5, 77.4, 64.3.

10

2-(4-Ethynylphenyl)ethan-1-ol (**57**)



15

To a solution of 2-(4-((trimethylsilyl)ethynyl)phenyl)ethan-1-ol (2.85 g, 13.07 mmol) in THF (26 mL) was added tetrabutylammonium fluoride solution (14.37 ml, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (10 ml). Water (10 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (1/1, v/v) to obtain the compound **57** as a white solid (1.67 mg, 94% yield):


20

¹H NMR (400 MHz, CDCl₃) δ 7.39 (d, *J* = 8.3 Hz, 2H), 7.10 (d, *J* = 8.3 Hz, 2H), 3.66 (td, *J* = 6.9, 2.7 Hz, 2H), 3.28 (bs, 1H), 3.09 (s, 1H), 2.72 (t, *J* = 6.8 Hz, 2H);

25

¹³C NMR (100 MHz, CDCl₃) δ 139.6, 132.0, 128.9, 119.8, 83.6, 7.2, 62.8, 38.7.


tert-Butyl(4-ethynylphenoxy)dimethylsilane (**58**)



30


To a solution of 4-ethynylphenol (511 mg, 4.33 mmol) and imidazole (295 mg, 4.33 mmol) in DMF (13 mL) was added TBDMSCl (652 mg, 4.33 mmol). This reaction mixture was stirred at ambient temperature for overnight. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DCM (10 ml). Water (10 mL) was added, and the aqueous layer
5 was extracted with DCM (10 mL X 2). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (10/1, v/v) to obtain the compound **58** as a brown solid (675 mg, 67% yield):
¹H NMR (400 MHz, CDCl₃) δ 7.41 (d, *J* = 8.6 Hz, 2H), 6.81 (d, *J* = 8.6 Hz, 2H), 3.02 (s, 1H), 1.01
10 (s, 9H), 0.23 (s, 6H);
¹³C NMR (100 MHz, CDCl₃) δ 156.4, 133.7, 120.3, 115.0, 83.8, 76.1, 25.8, 18.3, -4.3.

tert-Butyl((4-ethynylbenzyl)oxy)dimethylsilane (**59**)



To a solution of (4-ethynylphenyl)methanol (1.66 g, 12.54 mmol) and imidazole (1.71 g, 25.08 mmol) in DMF (37mL) was added TBDMSCl (2.84 g, 18.81 mmol). This reaction mixture was stirred at ambient temperature for overnight. All the volatile solvent was removed under
20 reduced pressure, and the residue was dissolved in DCM (10 ml). Water (10 mL) was added, and the aqueous layer was extracted with DCM (10 mL X 2). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (10/1, v/v) to obtain the compound **59** as a brown solid
25 (2.91 mg, 94% yield):
¹H NMR (400 MHz, CDCl₃) δ 7.46 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.8 Hz, 2H), 4.73 (s, 2H), 3.04 (s, 1H), 0.94 (s, 9H), 0.10 (s, 6H);
¹³C NMR (100 MHz, CDCl₃) δ 142.5, 132.2, 126.0, 120.6, 83.9, 64.7, 26.1, 18.5, -5.1.

30 *tert*-Butyl(4-ethynylphenethoxy)dimethylsilane (**60**)




To a solution of 2-(4-ethynylphenyl)ethan-1-ol (1.67 g, 11.40 mmol) and imidazole (1.55 g, 22.79 mmol) in DMF (34 mL) was added TBDMSCl (2.58 g, 17.09 mmol). This reaction mixture was stirred at ambient temperature for overnight. All the volatile solvent was removed under reduced pressure, and the residue was dissolved in DMF (34 ml). Water (10 mL) was added, and the aqueous layer was extracted with DCM (10 mL X 2). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (1/1, v/v) to obtain the compound **60** as a brown solid (2.67 g, 90% yield):

¹H NMR (400 MHz, CDCl₃) δ 7.45 (d, *J* = 8.2 Hz, 2H), 7.20 (d, *J* = 8.2 Hz, 2H), 3.84 (t, *J* = 6.8, 2H), 3.08 (s, 1H), 2.84 (t, *J* = 6.8 Hz, 2H), 0.93 (s, 9H), 0.03 (s, 6H);

¹³C NMR (100 MHz, CDCl₃) δ 140.3, 132.0, 129.2, 120.0, 83.9, 76.9, 64.1, 39.5, 26.0, 18.3, -5.4.

15 Methyl 4-amino-3-((4-((tert-butyldimethylsilyl)oxy)phenyl)ethynyl)benzoate (**61**)




A combined suspension of methyl 4-amino-3-iodobenzoate (1.21 g, 4.36 mmol), copper (I) iodide (17 mg, 0.87 mmol), bis(triphenylphosphine)palladium(II) dichloride (61 mg, 0.87 mmol), and *tert*-butyl(4-ethynylphenoxy)dimethylsilane (1.22 g, 5.23 mmol) were stirred in toluene and TEA (1/1, 36 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (5/1, v/v) to obtain the compound **61** as a brown solid (1.66 g, quant. yield):

¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 2.1 Hz, 1H), 7.80 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 2H), 6.82 (d, *J* = 8.6 Hz, 2H), 6.68 (d, *J* = 8.5 Hz, 1H), 4.73 (s, 2H), 3.86 (s, 3H), 0.99 (s, 9H), 0.22 (s, 6H);

¹³C NMR (100 MHz, CDCl₃) δ 166.8, 156.3, 151.5, 134.3, 133.1, 131.2, 120.4, 119.4, 115.7, 113.3, 107.6, 95.2, 83.6, 51.8, 25.7, 18.3, -4.3.


30

Methyl 4-amino-3-((4-(hydroxymethyl)phenyl)ethynyl)benzoate (**62**)




5 A combined suspension of methyl 4-amino-3-iodobenzoate (2.72 g, 9.83 mmol), copper (I) iodide (37 mg, 0.20 mmol), bis(triphenylphosphine)palladium(II) dichloride (138 mg, 0.20 mmol), and *tert*-butyl((4-ethynylbenzyl)oxy)dimethylsilane (2.91 g, 11.79 mmol) were stirred in toluene and TEA (1/1, 82 mL) at ambient temperature for overnight. The reaction solvent was
 10 evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (7/1, v/v) to obtain the compound **62** as a brown solid (3.89 g, quant. yield):

Methyl 4-amino-3-((4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)ethynyl)benzoate (**63**)




15 A combined suspension of methyl 4-amino-3-iodobenzoate (2.36 g, 8.53 mmol), copper (I) iodide (33 mg, 0.17 mmol), bis(triphenylphosphine)palladium(II) dichloride (120 mg, 0.17 mmol), and *tert*-butyl(4-ethynylphenethoxy)dimethylsilane (2.67 g, 10.23 mmol) were stirred in
 20 toluene and TEA (1/1, 72 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (3/1, v/v) to obtain the compound **63** as a brown solid (3.66 g, quant. yield):
¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 2.1 Hz, 1H), 7.75 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.39 (d, *J* = 8.2 Hz, 2H), 7.12 (d, *J* = 8.3 Hz, 2H), 6.62 (d, *J* = 8.6 Hz, 1H), 4.94 (s, 2H), 3.78 (s, 3H), 3.75
 25 (t, *J* = 6.7 Hz, 2H), 2.75 (t, *J* = 6.7 Hz, 2H), 0.85 (s, 9H), -0.05 (s, 6H);
¹³C NMR (100 MHz, CDCl₃) δ 166.4, 151.7, 139.9, 134.1, 131.1, 129.1, 120.3, 118.6, 113.0, 106.8, 95.0, 84.3, 63.8, 51.4, 39.2, 25.7, 18.0, -5.7.

N-(4-Ethynylphenyl)acetamide (**65**)

To a solution of 4-ethynylaniline (3.00 g, 25.61 mmol) in DCM (75 mL) was added acetic anhydride (2.71 ml, 28.68 mmol). After addition, the reaction was stirred at ambient temperature for 6 h. And the, water (75 mL) was added, and the aqueous layer was extracted with DCM (15 mL X 2). The combined organic layer was washed with brine (30 mL), dried over Na₂SO₄, and filtered. The organic layer was concentrated under reduced pressure and the residue was purified by silica gel chromatography, by column chromatography with hexane/ethyl acetate (2/1, v/v) to obtain the compound **65** as a white solid (3.41 g, 84% yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 10.10 (s, 1H), 7.59 (d, *J* = 8.7 Hz, 2H), 7.39 (d, *J* = 8.7 Hz, 2H), 4.06 (s, 1H), 2.05 (s, 3H);

¹³C NMR (100 MHz, DMSO-*d*₆) δ 168.5, 139.8, 132.3, 118.7, 115.8, 83.6, 79.7, 24.1.


Methyl 3-((4-acetamidophenyl)ethynyl)-4-aminobenzoate (**66**)

A combined suspension of methyl 4-amino-3-iodobenzoate (3.00 g, 10.83 mmol), copper (I) iodide (41 mg, 0.22 mmol), bis(triphenylphosphine)palladium(II) dichloride (152 mg, 0.22 mmol), and *N*-(4-ethynylphenyl)acetamide (2.07 g, 12.99 mmol) were stirred in toluene and TEA (1/1, 90 mL) at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with hexane/ethyl acetate (1/1, v/v) to obtain the compound **66** as a white solid (2.18 g, 65% yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.10 (s, 1H), 7.80 (d, *J* = 2.0 Hz, 1H), 7.65 – 7.56 (m, 5H), 6.75 (d, *J* = 8.7 Hz, 1H), 6.33 (s, 2H), 3.76 (s, 3H), 2.06 (s, 3H);

^{13}C NMR (100 MHz, $\text{DMSO-}d_6$) δ 168.5, 165.7, 153.4, 139.5, 133.6, 132.1, 130.8, 118.6, 116.8, 116.2, 113.2, 105.2, 94.4, 84.6, 51.5, 24.1.


5 Methyl (Z)-3-(chloro(4-nitrophenyl)methylene)-2-oxoindoline-5-carboxylate (**79**)



To a solution of triphosgene (371 mg, 1.25 mmol) in toluene (169 mL) were added methyl
 10 4-amino-3-((4-nitrophenyl)ethynyl)benzoate (1.00 g, 3.38 mmol) and TEA (1.04 mL, 7.43 mmol).
 After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was
 removed under reduced pressure, the crude methyl 4-isocyanato-3-((4-
 nitrophenyl)ethynyl)benzoate was obtained as a solid (2.14 g), and then directly was used to next
 step. This solid compound (2.14 g, 6.85 mmol) was dissolved in DCM (69 mL). FeCl_3 (1.67 g,
 15 10.27 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature
 for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was
 purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major
 compound **79** as a yellow solid (624 mg, 52% yield):

^1H NMR (400 MHz, $\text{DMSO-}d_6$) δ 11.15 (s, 1H), 8.69 (d, $J = 1.6$ Hz, 1H), 8.30 (d, $J = 8.9$ Hz, 2H),
 20 8.01 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.86 (d, $J = 8.9$ Hz, 2H), 7.00 (d, $J = 8.2$ Hz, 1H), 3.86 (s, 3H).

Methyl (Z)-3-(chloro(4-(methoxycarbonyl)phenyl)methylene)-2-oxoindoline-5-carboxylate (**80**)




25

To a solution of triphosgene (355 mg, 1.20 mmol) in toluene (162 mL) were added methyl 4-amino-3-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (1.00 g, 3.23 mmol) and TEA (0.99 mL, 7.11 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 4-isocyanato-3-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate was obtained as a solid (2.08 g), and then directly
5 was used to next step. This solid compound (2.08 g, 6.19 mmol) was dissolved in DCM (62 mL). FeCl₃ (1.51 g, 9.29 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain
10 the major compound **80** as a yellow solid (304 mg, 25% yield):
¹H NMR (400 MHz, CDCl₃) δ 8.88 (s, 1H), 8.11 (d, *J* = 8.7 Hz, 2H), 8.05 (dd, *J* = 8.2, 1.6 Hz, 2H), 7.61 (d, *J* = 8.8 Hz, 2H), 6.85 (d, *J* = 8.2 Hz, 1H), 3.94 (s, 6H).

Methyl (Z)-3-(chloro(3-nitrophenyl)methylene)-2-oxoindoline-5-carboxylate (**81**)

15




To a solution of triphosgene (371 mg, 1.25 mmol) in toluene (169 mL) were added methyl 4-amino-3-((3-nitrophenyl)ethynyl)benzoate (1.00 g, 3.36 mmol) and TEA (1.04 mL, 7.43 mmol).
20 After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 4-isocyanato-3-((3-nitrophenyl)ethynyl)benzoate was obtained as a solid (4.45 g), and then directly was used to next step. This solid compound (4.45 g, 13.81 mmol) was dissolved in DCM (138 mL). FeCl₃ (3.36 g, 20.72 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature
25 for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **81** as a yellow solid (820 mg, 68% yield):
¹H NMR (400 MHz, DMSO-d₆) δ 11.27 (s, 1H), 8.50 (d, *J* = 1.5 Hz, 2H), 8.11 (d, *J* = 8.0 Hz, 1H), 7.94 (t, *J* = 8.3 Hz, 1H), 7.81 (dd, *J* = 8.3, 1.7 Hz, 1H), 6.73 (d, *J* = 1.6 Hz, 1H), 3.63 (s, 3H).

30

Methyl (Z)-3-(chloro(*p*-tolyl)methylene)-2-oxoindoline-5-carboxylate (**82**)


5



To a solution of triphosgene (414 mg, 1.40 mmol) in toluene (189 mL) were added methyl 4-amino-3-(*p*-tolylethynyl)benzoate (1.00 g, 3.77 mmol) and TEA (1.16 mL, 8.29 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 4-isocyanato-3-(*p*-tolylethynyl)benzoate was obtained as a solid (2.70 g), and then directly was used to next step. This solid compound (2.70 g, 9.27 mmol) was dissolved in DCM (93 mL). FeCl₃ (2.26 g, 13.91 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **82** as a yellow solid (1.24 g, quant. yield):

Methyl (Z)-3-(chloro(4-ethylphenyl)methylene)-2-oxoindoline-5-carboxylate (**83**)

20




To a solution of triphosgene (393 mg, 1.32 mmol) in toluene (180 mL) were added methyl 4-amino-3-((4-ethylphenyl)ethynyl)benzoate (1.00 g, 3.58 mmol) and TEA (1.10 mL, 7.88 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 3-((4-ethylphenyl)ethynyl)-4-

isocyanatobenzoate was obtained as a solid (2.60 g), and then directly was used to next step. This solid compound (2.60 g, 8.51 mmol) was dissolved in DCM (85 mL). FeCl₃ (2.07 g, 12.76 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **83** as a yellow solid (1.22 g, quant. yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.05 (s, 1H), 8.68 (d, *J* = 1.6 Hz, 1H), 7.95 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.50 (d, *J* = 8.2 Hz, 2H), 7.28 (d, *J* = 8.3 Hz, 2H), 6.95 (d, *J* = 8.2 Hz, 1H), 3.84 (s, 3H), 2.67 (q, *J* = 7.6 Hz, 2H), 1.22 (t, *J* = 7.6 Hz, 3H);

¹³C NMR (125 MHz, DMSO-*d*₆) δ 166.0, 165.3, 146.5, 146.2, 146.1, 134.3, 132.1, 129.5, 127.3, 125.5, 123.7, 122.5, 122.4, 109.6, 52.1, 28.1, 15.3.

Methyl (Z)-3-(chloro(4-methoxyphenyl)methylene)-2-oxoindoline-5-carboxylate (**84**)



15


To a solution of triphosgene (390 mg, 1.32 mmol) in toluene (178 mL) were added methyl 4-amino-3-((4-methoxyphenyl)ethynyl)benzoate (1.00 g, 3.56 mmol) and TEA (1.09 mL, 7.82 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 4-isocyanato-3-((4-methoxyphenyl)ethynyl)benzoate was obtained as a solid (2.30 g), and then directly was used to next step. This solid compound (2.30 g, 7.48 mmol) was dissolved in DCM (75 mL). FeCl₃ (1.82 g, 11.23 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **84** as a yellow solid (932 mg, 76% yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.01 (s, 1H), 8.68 (d, *J* = 1.7 Hz, 1H), 7.93 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.56 (d, *J* = 8.9 Hz, 2H), 6.97 (d, *J* = 8.9 Hz, 2H), 6.94 (dd, *J* = 8.2, 0.6 Hz, 1H), 3.83 (s, 3H), 3.82 (s, 3H).

30


Methyl (Z)-3-(chloro(3-methoxyphenyl)methylene)-2-oxoindoline-5-carboxylate (**85**)

5



To a solution of triphosgene (390 mg, 1.32 mmol) in toluene (178 mL) were added methyl 4-amino-3-((4-methoxyphenyl)ethynyl)benzoate (1.00 g, 3.56 mmol) and TEA (1.09 mL, 7.82 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 4-isocyanato-3-((4-methoxyphenyl)ethynyl)benzoate was obtained as a solid (2.27 g), and then directly was used to next step. This solid compound (2.27 g, 7.38 mmol) was dissolved in DCM (74 mL). FeCl₃ (1.80 g, 11.08 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **85** as a yellow solid (887 mg, 73% yield):

20

Methyl (Z)-3-(benzo[d][1,3]dioxol-5-ylchloromethylene)-2-oxoindoline-5-carboxylate (**86**)


To a solution of triphosgene (372 mg, 1.25 mmol) in toluene (169 mL) were added methyl 4-amino-3-(benzo[d][1,3]dioxol-5-ylethynyl)benzoate (1.00 g, 3.39 mmol) and TEA (1.04 mL, 7.45 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 3-(benzo[d][1,3]dioxol-5-

ylethynyl)-4-isocyanatobenzoate was obtained as a solid (2.18 g), and then directly was used to next step. This solid compound (2.18 g, 6.77 mmol) was dissolved in DCM (68 mL). FeCl₃ (1.65 g, 10.15 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **86** as a yellow solid (1.21 g, quant. yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.02 (s, 1H), 8.67 (s, 1H), 7.95 (d, *J* = 8.1 Hz, 1H), 7.18 (s, 1H), 7.13 (d, *J* = 8.2 Hz, 1H), 7.00 – 6.95 (m, 2H), 6.12 (s, 2H), 3.85 (s, 3H);

¹³C NMR (125 MHz, DMSO-*d*₆) δ 166.0, 165.3, 149.1, 146.7, 146.0, 145.3, 132.0, 130.4, 125.4, 124.5, 123.7, 122.5, 122.4, 109.9, 109.5, 107.9, 101.7, 52.1.

Methyl (Z)-3-((4-((*tert*-butyldimethylsilyl)oxy)phenyl)chloromethylene)-2-oxoindoline-5-carboxylate (**87**)




To a solution of triphosgene (288 mg, 0.97 mmol) in toluene (131 mL) were added methyl 4-amino-3-((3-nitrophenyl)ethynyl)benzoate (1.00 g, 2.62 mmol) and TEA (0.80 mL, 5.77 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 3-((4-((*tert*-butyldimethylsilyl)oxy)phenyl)ethynyl)-4-isocyanatobenzoate was obtained as a solid (2.12 g), and then directly was used to next step. This solid compound (2.12 g, 5.19 mmol) was dissolved in DCM (52 mL). FeCl₃ (1.26 g, 7.79mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **87** as a yellow solid (218 mg, 19% yield):

¹H NMR (400 MHz, CDCl₃) δ 10.08 (s, 1H), 7.86 (d, *J* = 8.2 Hz, 1H), 7.44 (d, *J* = 8.7 Hz, 2H), 7.33 (s, 1H), 6.96 (dd, *J* = 8.5, 2.1 Hz, 3H), 3.74 (s, 3H), 1.03 (s, 9H), 0.29 (s, 6H);

¹³C NMR (100 MHz, CDCl₃) δ 168.2, 166.7, 158.4, 145.4, 143.2, 131.5, 130.7, 130.5, 124.1, 123.5, 123.2, 122.3, 120.7, 109.9, 52.0, 25.7, 25.7, 18.3, -4.28, -4.30.


Methyl (Z)-3-(chloro(4-(hydroxymethyl)phenyl)methylene)-2-oxoindoline-5-carboxylate (**88**)

5



To a solution of triphosgene (278 mg, 0.94 mmol) in toluene (126 mL) were added methyl
 4-amino-3-((4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)ethynyl)benzoate (1.00 g, 2.53
 10 mmol) and TEA (0.78 mL, 5.56 mmol). After addition, the reaction was stirred at ambient
 temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl
 3-((4-(((*tert*-butyldimethylsilyl)oxy)methyl)phenyl)ethynyl)-4-isocyanatobenzoate was obtained
 as a solid (2.04 g), and then directly was used to next step. This solid compound (2.04 g, 4.85
 15 mmol) was dissolved in DCM (49 mL). FeCl₃ (1.18 g, 7.27 mmol) was added to the solution. The
 reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was
 evaporated under reduced pressure, and the residue was purified by column chromatography with
 ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **88** as a yellow solid (869 mg, 34%
 yield):

20 Methyl (Z)-3-((4-(2-(((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)chloromethylene)-2-oxoindoline-
 5-carboxylate (**89**)



25 To a solution of triphosgene (268 mg, 0.90 mmol) in toluene (122 mL) were added methyl
 4-amino-3-((4-(2-(((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)ethynyl)benzoate (1.00 g, 2.44

mmol) and TEA (0.75 mL, 5.37 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 3-((4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)ethynyl)-4-isocyanatobenzoate was obtained as a solid (2.00 g), and then directly was used to next step. This solid compound (2.00 g, 4.60


5 mmol) was dissolved in DCM (46 mL). FeCl₃ (1.12 g, 6.90 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **89** as a yellow solid (247 mg, 21% yield):

10 ¹H NMR (500 MHz, CDCl₃) δ 9.10 (s, 1H), 8.28 (s, 1H), 8.22 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.72 (d, *J* = 8.2 Hz, 2H), 7.50 (d, *J* = 8.2 Hz, 2H), 7.47 (s, 1H). 7.02 (d, *J* = 8.2 Hz, 1H), 4.15 (s, 3H), 4.06 (t, *J* = 7.1 Hz, 2H), 3.10 (t, *J* = 7.1 Hz, 2H), 1.10 (s, 9H), 0.23 (s, 6H);

¹³C NMR (125MHz, CDCl₃) δ 167.0, 166.2, 149.0, 144.2, 142.4, 135.0, 132.2, 129.4, 129.0, 126.9, 124.3, 123.4, 123.2, 109.2, 64.3, 52.3, 39.7, 26.1, 18.5, 0.2, -5.2.

15

Methyl (Z)-3-((4-acetamidophenyl)chloromethylene)-2-oxoindoline-5-carboxylate (**90**)




20 To a solution of triphosgene (107 mg, 0.36 mmol) in toluene (49 mL) were added methyl 3-((4-acetamidophenyl)ethynyl)-4-aminobenzoate (300 mg, 0.97 mmol) and TEA (0.30 mL, 2.14 mmol). After addition, the reaction was stirred at ambient temperature for 3h. All the volatile solvent was removed under reduced pressure, the crude methyl 3-((4-acetamidophenyl)ethynyl)-4-isocyanatobenzoate was obtained as a solid (628 mg), and then directly was used to next step.

25 This solid compound (628 mg, 1.88 mmol) was dissolved in DCM (19 mL). FeCl₃ (455 mg, 2.82 mmol) was added to the solution. The reaction mixture was stirred at ambient temperature for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with ethyl acetate/ethanol (50/1, v/v) to obtain the major compound **90** as a yellow solid (186 mg, 52% yield):

^1H NMR (400 MHz, CDCl_3) δ 12.24 (s, 1H), 8.03 (d, $J = 2.0$ Hz, 1H), 8.00 (s, 1H), 7.78 (dd, $J = 8.5, 2.1$ Hz, 2H), 7.52 (d, $J = 8.7$ Hz, 2H), 7.42 (d, $J = 8.6$ Hz, 2H), 6.67 (d, $J = 8.6$ Hz, 1H), 3.85 (s, 3H), 2.15 (s, 3H), 2.05 (s, 3H).

- 5 Methyl (Z)-3-(((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(4-nitrophenyl)methylene)-2-oxindoline-5-carboxylate (**91**)




- 10 A solution of methyl (Z)-3-(chloro(4-nitrophenyl)methylene)-2-oxindoline-5-carboxylate (188 mg, 0.52 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (158 mg, 0.60 mmol) and TEA (0.15 mL, 1.05 mmol) in EtOH (1.5 mL) was stirred under reflux for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final
15 compound **91** as a yellow solid (267 mg, 87% yield):

^1H NMR (500 MHz, $\text{DMSO}-d_6$) δ 11.85 (s, 1H), 11.20 (s, 1H), 8.44 (d, $J = 8.4$ Hz, 2H), 7.88 (d, $J = 8.4$ Hz, 2H), 7.59 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.16 (d, $J = 8.1$ Hz, 2H), 6.99 (d, $J = 8.2$ Hz, 2H), 6.96 (d, $J = 8.2$ Hz, 1H), 6.27 (s, 1H), 3.59 (s, 3H), 3.06 (bs, 2H), 2.66 (bs, 2H), 2.14 (bs, 6H), 2.08 (s, 3H);

- 20 ^{13}C NMR (125 MHz, $\text{DMSO}-d_6$) δ 170.2, 168.6, 166.2, 154.7, 148.2, 140.7, 140.5, 138.9, 136.9, 130.8, 127.9, 125.8, 124.5, 123.4, 121.3, 119.1, 109.1, 97.6, 59.2, 54.5, 52.4, 51.6, 45.7, 36.7;
HRMS (ESI-TOF) m/z calcd for $\text{C}_{31}\text{H}_{32}\text{N}_6\text{O}_6$ [$\text{M} + \text{Na}^+$] 607.2276 found 607.2278.

25

Methyl (Z)-3-((4-(methoxycarbonyl)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**92**)



5

A solution of methyl (Z)-3-(chloro(4-(methoxycarbonyl)phenyl)methylene)-2-oxoindoline-5-carboxylate (10 mg, 0.03 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (81 mg, 0.04 mmol) and TEA (0.5 μ L, 0.04 mmol) in EtOH (0.3 mL) was stirred under reflux for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **92** as a yellow solid (9.4 mg, 59% yield):


10

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 11.95 (s, 1H), 8.24 (d, $J = 8.5$ Hz, 2H), 7.93 (s, 1H), 7.74 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.57 (d, $J = 8.5$ Hz, 2H), 6.99 (d, $J = 8.4$ Hz, 2H), 6.94 (dd, $J = 8.2, 0.6$ Hz, 1H), 6.79 (d, $J = 8.6$ Hz, 2H), 6.67 (s, 1H), 3.99 (s, 3H), 3.71 (s, 3H), 3.17 (bs, 2H), 2.78 (bs, 2H), 2.38

15

(bs, 4H), 2.25 (s, 3H), 1.25 (s, 6H)..

Methyl (Z)-3-(((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(3-nitrophenyl)methylene)-2-oxoindoline-5-carboxylate (**93**)




20

A solution of methyl (*Z*)-3-(chloro(3-nitrophenyl)methylene)-2-oxoindoline-5-carboxylate (58 mg, 0.16 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (48 mg, 0.18 mmol) and TEA (0.05 mL, 0.32 mmol) in EtOH (0.5 mL) was stirred under reflux for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **93** as a yellow solid (84 mg, 90% yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.86 (s, 1H), 11.21 (s, 1H), 8.48 (dd, *J* = 7.6, 1.4 Hz, 2H), 8.00 (d, *J* = 7.8 Hz, 1H), 7.87 (t, *J* = 8.1 Hz, 1H), 7.60 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.16 (d, *J* = 8.2 Hz, 2H), 7.00 (d, *J* = 8.2 Hz, 2H), 6.96 (d, *J* = 8.2 Hz, 1H), 6.42 (s, 1H), 3.62 (s, 3H), 3.05 (bs, 2H), 2.14 (bs, 5H), 2.09 (s, 3H);

HRMS (ESI-TOF) *m/z* calcd for C₃₁H₃₂N₆O₆ [M + H⁺] 584.2383 found 585.2459.

Methyl (*Z*)-3-(((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(*p*-tolyl)methylene)-2-oxoindoline-5-carboxylate (**94**)



A solution of methyl (*Z*)-3-(chloro(*p*-tolyl)methylene)-2-oxoindoline-5-carboxylate (100 mg, 0.31 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (92 mg, 0.35 mmol) and TEA (0.09 mL, 0.61 mmol) in EtOH (1.0 mL) was stirred under reflux for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **94** as a yellow solid (169 mg, quant. yield):


¹H NMR (500 MHz, DMSO-*d*₆) δ 11.94 (s, 1H), 11.12 (s, 1H), 7.57 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.40 – 7.36 (m, 4H), 7.14 (d, *J* = 8.1 Hz, 2H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.90 (d, *J* = 8.3 Hz, 2H), 6.50 (s, 1H), 3.64 (s, 3H), 3.05 (bs, 2H), 2.69 (bs, 1H), 2.43 (s, 3H), 2.19 (bs, 6H), 2.10 (s, 3H);

^{13}C NMR (125 MHz, DMSO- d_6) δ 170.4, 168.6, 166.4, 157.3, 140.4, 140.0, 139.8, 137.5, 130.0, 129.3, 128.4, 127.8, 125.4, 124.1, 123.6, 121.3, 120.0, 108.8, 97.5, 59.2, 54.6, 52.4, 51.6, 45.8, 36.7, 21.1;

HRMS (ESI-TOF) m/z calcd for $\text{C}_{31}\text{H}_{32}\text{N}_6\text{O}_6$ $[\text{M} + \text{H}^+]$ 553.2689 found 554.2772.

5

Methyl (Z)-3-((4-ethylphenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**95**)



10

A solution of methyl (Z)-3-(chloro(4-ethylphenyl)methylene)-2-oxoindoline-5-carboxylate (100 mg, 0.29 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (88 mg, 0.34 mmol) and TEA (0.08 mL, 0.59 mmol) in EtOH (1.0 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **95** as a yellow solid (166 mg, quant. yield):

15

^1H NMR (500 MHz, DMSO- d_6) δ 11.95 (s, 1H), 11.13 (s, 1H), 7.58 (dd, $J = 8.2, 1.7$ Hz, 1H), 7.42 – 7.38 (m, 5H), 7.13 (d, $J = 8.2$ Hz, 2H), 6.93 (d, $J = 8.2$ Hz, 1H), 6.89 (d, $J = 8.2$ Hz, 2H), 6.51 (s, 1H), 3.62 (s, 3H), 3.05 (bs, 2H), 2.72 (q, $J = 7.6$ Hz, 2H), 2.68 (bs, 2H), 2.18 (bs, 2H), 2.10 (s, 3H), 1.27 (t, $J = 7.6$ Hz, 3H);


20

^{13}C NMR (125 MHz, DMSO- d_6) δ 170.4, 168.6, 166.4, 157.3, 146.4, 140.4, 139.8, 137.5, 129.5, 128.9, 128.5, 127.7, 125.6, 124.0, 123.6, 121.3, 119.5, 108.9, 97.5, 59.2, 54.6, 52.4, 51.5, 45.8, 36.7, 28.3, 15.8;

HRMS (ESI-TOF) m/z calcd for $\text{C}_{31}\text{H}_{32}\text{N}_6\text{O}_6$ $[\text{M} + \text{H}^+]$ 567.2846 found 568.2941.

25

Methyl (Z)-3-((4-methoxyphenyl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**96**)



5

A solution of methyl (Z)-3-(chloro(4-methoxyphenyl)methylene)-2-oxoindoline-5-carboxylate (100 mg, 0.29 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (88 mg, 0.34 mmol) and TEA (0.08 mL, 0.59 mmol) in EtOH (1.0 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **96** as a yellow solid (164 mg, 99% yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.91 (s, 1H), 11.12 (s, 1H), 7.59 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.43 (d, *J* = 8.6 Hz, 2H), 7.15 (d, *J* = 8.8 Hz, 3H), 6.94 (d, *J* = 8.2 Hz, 1H), 6.90 (d, *J* = 8.4 Hz, 2H), 6.65 (d, *J* = 1.5 Hz, 1H), 3.87 (s, 3H), 3.65 (s, 3H), 3.07 (bs, 3H), 2.87 (bs, 2H), 2.65 (bs, 4H);


¹³C NMR (125 MHz, DMSO-*d*₆) δ 170.4, 166.4, 160.7, 156.8, 140.4, 139.1, 130.2, 127.8, 125.4, 124.15, 124.09, 123.4, 121.2, 119.6, 115.0, 108.8, 97.8, 57.7, 55.5, 52.6, 51.5, 49.1;

HRMS (ESI-TOF) *m/z* calcd for C₃₂H₃₅N₅O₅ [M + Na⁺] 592.2530, found 592.2531.

20

25

Methyl (Z)-3-((3-methoxyphenyl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**97**)



5

A solution of methyl (Z)-3-(chloro(3-methoxyphenyl)methylene)-2-oxoindoline-5-carboxylate (150 mg, 0.44 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (132 mg, 0.50 mmol) and TEA (0.12 mL, 0.87 mmol) in EtOH (1.2 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **97** as a yellow solid (172 mg, 69% yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.98 (s, 1H), 11.12 (s, 1H), 7.59 (d, *J* = 8.3 Hz, 1H), 7.49 (t, *J* = 8.0 Hz, 1H), 7.19 – 7.14 (m, 3H), 7.10 (s, 1H), 7.05 (d, *J* = 7.6 Hz, 1H), 6.93 (t, *J* = 8.4 Hz, 3H), 6.65 (s, 1H), 3.74 (s, 3H), 3.66 (s, 3H), 3.06 (bs, 2H), 2.70 (bs, 2H), 2.19 (bs, 2H), 2.10 (s, 3H);

¹³C NMR (125 MHz, DMSO-*d*₆) δ 170.4, 168.6, 166.4, 160.0, 156.7, 140.4, 139.9, 133.3, 130.8, 127.7, 125.5, 123.8, 123.5, 121.3, 120.5, 119.7, 115.9, 114.0, 108.8, 97.3, 59.1, 55.5, 54.6, 52.4, 51.5, 45.8;


15

HRMS (ESI-TOF) *m/z* calcd for C₃₂H₃₅N₅O₅ [M + H⁺] 570.2711, found 570.2714.

20

25

Methyl (Z)-3-(benzo[d][1,3]dioxol-5-yl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**98**)



5

A solution of methyl (Z)-3-(benzo[d][1,3]dioxol-5-ylchloromethylene)-2-oxoindoline-5-carboxylate (150 mg, 0.42 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (127 mg, 0.48 mmol) and TEA (0.12 mL, 0.84 mmol) in EtOH (1.2 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **98** as a yellow solid (179 mg, 73% yield):

10

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.85 (s, 1H), 11.10 (s, 1H), 7.60 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.18 (d, *J* = 8.3 Hz, 2H), 7.11 (d, *J* = 8.1 Hz, 1H), 7.10 (s, 1H), 6.98 (dd, *J* = 8.0, 1.7 Hz, 1H), 6.95 – 6.93 (m, 3H), 6.72 (s, 1H), 6.16 (s, 1H), 6.12 (s, 1H), 3.69 (s, 3H), 3.08 (bs, 2H), 2.73 (bs, 2H), 2.21 (bs, 3H), 2.11 (s, 3H);

15


¹³C NMR (125 MHz, DMSO-*d*₆) δ 170.4, 168.6, 166.4, 156.6, 148.7, 148.1, 140.4, 139.9, 127.8, 125.6, 125.4, 124.0, 123.5, 122.8, 121.3, 119.6, 109.4, 109.0, 108.8, 101.7, 97.6, 59.2, 54.6, 52.3, 51.6, 45.7, 36.7;

HRMS (ESI-TOF) *m/z* calcd for C₃₂H₃₃N₅O₆ [M + H⁺] 584.2504, found 584.2509.

20

25

Methyl (Z)-3-((4-((*tert*-butyldimethylsilyl)oxy)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**99**)



5

A solution of methyl (Z)-3-((4-((*tert*-butyldimethylsilyl)oxy)phenyl)chloromethylene)-2-oxoindoline-5-carboxylate (200 mg, 0.45 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (136 mg, 0.52 mmol) and TEA (0.13 mL, 0.90 mmol) in EtOH (1.3 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **99** (166 mg, 54% yield):


¹H NMR (500 MHz, CDCl₃) δ 11.93 (s, 1H), 10.08 (s, 1H), 7.74 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.31 (d, *J* = 8.5 Hz, 2H), 7.05 (s, 1H), 7.00 (dd, *J* = 8.3, 1.7 Hz, 3H), 6.97 (d, *J* = 8.4 Hz, 2H), 6.75 (d, *J* = 8.8 Hz, 2H), 3.75 (s, 3H), 3.19 (s, 3H), 2.84 (s, 2H), 2.44 (bs, 6H), 2.27 (s, 3H), 1.04 (s, 9H), 0.91 (s, 2H), 0.29 (s, 6H);

¹³C NMR (125 MHz, CDCl₃) δ 171.5, 169.6, 167.5, 157.9, 157.4, 139.9, 139.4, 138.5, 130.4, 127.8, 126.2, 124.9, 124.4, 123.6, 122.7, 121.4, 120.5, 109.1, 98.3, 59.7, 54.9, 53.3, 51.8, 46.1, 37.5, 25.7, 18.4, -3.4, -4.3.

20

25

Methyl (Z)-3-((4-(hydroxymethyl)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**100**)




A solution of methyl (Z)-3-(chloro(4-(hydroxymethyl)phenyl)methylene)-2-oxoindoline-5-carboxylate (17 mg, 0.05 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (15 mg, 0.06 mmol) and TEA (0.1 μ L, 0.10 mmol) in EtOH (0.1 μ L) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **100** (15 mg, 52% yield):

^1H NMR (500 MHz, DMSO- d_6) δ 11.97 (s, 1H), 11.13 (s, 1H), 7.57 (d, $J = 8.2$ Hz, 1H), 7.51 (d, $J = 7.8$ Hz, 2H), 7.44 (d, $J = 7.8$ Hz, 2H), 7.13 (d, $J = 8.2$ Hz, 2H), 6.93 (d, $J = 8.3$ Hz, 1H), 6.90 (d, $J = 8.2$ Hz, 2H), 6.51 (s, 1H), 5.49 (bs, 1H), 4.64 (s, 2H), 3.63 (s, 3H), 3.05 (bs, 2H), 2.69 (bs, 2H), 2.18 (bs, 6H), 2.10 (s, 3H);

^{13}C NMR (125 MHz, DMSO- d_6) δ 170.4, 168.6, 166.4, 157.2, 145.0, 140.4, 139.8, 130.3, 128.3, 127.8, 127.7, 127.0, 125.5, 124.0, 123.6, 121.3, 119.6, 108.8, 97.6, 62.4, 59.2, 54.6, 52.5, 52.4, 51.6, 51.5, 45.8, 36.7;

HRMS (ESI-TOF) m/z calcd for $\text{C}_{31}\text{H}_{32}\text{N}_6\text{O}_6$ $[\text{M} + \text{H}^+]$ 569.2638 found 570.2713.

Methyl (Z)-3-((4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**101**)



5

A solution of methyl (Z)-3-((4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)chloromethylene)-2-oxoindoline-5-carboxylate (138 mg, 0.29 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (88 mg, 0.34 mmol) and TEA (0.8 μ L, 0.10 mmol) in EtOH (0.8 mL) was stirred under reflux for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **101** (154 mg, 76% yield):

10

$^1\text{H NMR}$ (500 MHz, CDCl_3) δ 12.03 (s, 1H), 10.04 (s, 1H), 7.73 (dd, $J = 8.2, 1.6$ Hz, 1H), 7.45 (d, $J = 7.9$ Hz, 2H), 7.39 (d, $J = 8.2$ Hz, 2H), 6.99 (d, $J = 8.2$ Hz, 3H), 6.84 (d, $J = 8.7$ Hz, 2H), 6.69 (d, $J = 1.7$ Hz, 1H), 3.95 (t, $J = 7.0$ Hz, 2H), 3.75 (s, 3H), 3.20 (s, 2H), 3.00 (t, $J = 7.0$, 2H), 2.45 (bs, 6H), 2.28 (s, 3H), 0.92 (s, 9H), 0.07 (s, 6H);


15

$^{13}\text{C NMR}$ (125MHz, CDCl_3) δ 171.4, 169.5, 167.4, 157.3, 142.3, 139.9, 139.3, 138.5, 130.5, 130.1, 128.4, 128.3, 127.9, 126.2, 124.3, 123.2, 122.6, 120.7, 115.7, 109.0, 98.6, 64.3, 59.6, 54.9, 53.3, 51.7.

20

25

Methyl (Z)-3-((4-acetamidophenyl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**102**)



5

A solution of methyl (Z)-3-((4-acetamidophenyl)chloromethylene)-2-oxoindoline-5-carboxylate (10 mg, 0.03 mmol), *N*-(4-aminophenyl)-*N*-methyl-2-(4-methylpiperazin-1-yl)acetamide (8.1 mg, 0.03 mmol) and TEA (0.01 mL, 0.06 mmol) in EtOH (0.1 mL) was stirred under refluxed for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **102** as a yellow solid (14 mg, 88% yield):


¹H NMR (400 MHz, DMSO-*d*₆) δ 11.89 (s, 1H), 11.12 (s, 1H), 10.26 (s, 1H), 7.77 (d, *J* = 8.6 Hz, 2H), 7.58 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.41 (d, *J* = 8.6 Hz, 2H), 7.15 (d, *J* = 8.2 Hz, 2H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.90 (d, *J* = 5.0 Hz, 2H), 6.69 (s, 1H), 3.64 (s, 3H), 3.06 (bs, 2H), 2.67 (bs, 2H), 2.18 (bs, 4H), 2.11 (s, 3H), 2.10 (bs, 2H);

HRMS (ESI-TOF) *m/z* calcd for C₃₃H₃₆N₆O₅ [M + H⁺] 596.2747 found 597.2818.

20

25

Methyl (Z)-3-((4-aminophenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**103**)




To a solution of methyl (Z)-3-((4-aminophenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (70 mg, 0.12 mmol) in EtOH (12 mL) was added SnCl₂ (91 mg, 0.48 mmol). This reaction mixture was stirred at 70 °C for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **103** as a yellow solid (66 mg, quant.% yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.79 (s, 1H), 11.03 (s, 1H), 7.58 (dd, *J* = 8.2, 1.8 Hz, 1H), 7.18 (d, *J* = 8.3 Hz, 2H), 7.10 (d, *J* = 8.3 Hz, 3H), 6.92 (d, *J* = 8.2 Hz, 1H), 6.88 (d, *J* = 8.3 Hz, 2H), 6.68 (d, *J* = 8.3 Hz, 2H), 5.76 (bs, 2H), 3.69 (s, 3H), 3.08 (bs, 2H), 2.89 (bs, 2H), 2.71 (bs, 4H), 2.50 (s, 3H);

¹³C NMR (125 MHz, DMSO-*d*₆) δ 170.5, 168.2, 166.6, 158.1, 151.0, 140.2, 138.7, 129.9, 127.8, 125.1, 124.5, 123.1, 121.2, 119.9, 117.9, 113.9, 108.6, 97.3, 57.7, 56.0, 52.6, 51.6, 48.9, 48.6, 36.7; HRMS (ESI-TOF) *m/z* calcd for C₃₁H₃₄N₆O₄ [M + Na⁺] 577.2534, found 577.2537.

Methyl (Z)-3-((3-aminophenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**104**)



5

To a solution of methyl (Z)-3-(((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)(3-nitrophenyl)methylene)-2-oxoindoline-5-carboxylate (13 mg, 0.12 mmol) in EtOH (2.1 mL) was added SnCl₂ (17 mg, 0.09 mmol). This reaction mixture was stirred at 70 °C for overnight. The reaction solvent was evaporated under reduced pressure, and the residue was purified by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **104** as a yellow solid (9.2 mg, 76% yield):

10


¹H NMR (400 MHz, DMSO-*d*₆) δ 12.03 (s, 1H), 11.10 (s, 1H), 7.59 (dd, *J* = 8.2, 1.7 Hz, 2H), 7.26 (t, *J* = 7.8 Hz, 2H), 7.18 (d, *J* = 8.2 Hz, 2H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.82 – 6.78 (m, 2H), 6.63 (d, *J* = 7.5 Hz, 1H), 6.59 (s, 1H), 5.44 (bs, 2H), 3.67 (s, 3H), 3.08 (bs, 2H), 2.91 (bs, 2H), 2.67 (bs, 2H), 2.50 (s, 3H);

15

HRMS (ESI-TOF) *m/z* calcd for C₃₁H₃₂N₆O₆ [*M* + H⁺] 554.2642 found 555.2706.

Methyl (Z)-3-((4-hydroxyphenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**105**)

20




To a solution of methyl (Z)-3-((4-((*tert*-butyldimethylsilyl)oxy)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (132 mg, 0.20 mmol) in THF (1.0 mL) was added tetrabutylammonium fluoride solution (0.22 mL, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography, by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **105** (95 mg, 87% yield):

¹H NMR (400 MHz, DMSO-*d*₆) δ 11.87 (s, 1H), 11.07 (s, 1H), 10.07 (bs, 1H), 7.58 (dd, *J* = 8.2, 1.7 Hz, 1H), 7.27 (d, *J* = 8.6 Hz, 2H), 7.15 (d, *J* = 8.2 Hz, 2H), 6.94 – 6.90 (m, 3H), 6.86 (d, *J* = 8.4 Hz, 2H), 6.81 (d, *J* = 1.6 Hz, 1H), 3.67 (s, 3H), 3.07 (bs, 2H), 2.72 (bs, 2H), 2.21 (bs, 6H), 2.10 (s, 3H);

HRMS (ESI-TOF) *m/z* calcd for C₃₁H₃₂N₆O₆ [M + H⁺] 555.2482 found 556.2560.

15 Methyl (Z)-3-((4-(2-hydroxyethyl)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (**106**)



20 To a solution of methyl (Z)-3-((4-(2-((*tert*-butyldimethylsilyl)oxy)ethyl)phenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (154 mg, 0.22 mmol) in THF (1.0 mL) was added tetrabutylammonium fluoride solution (0.24 mL, 1M in THF). After addition, the reaction was stirred at ambient temperature for 2 h. All the volatile solvent was removed under reduced pressure, and the residue was purified by silica gel chromatography, by column chromatography with dichloromethane/ethanol (50/1, v/v) to obtain the final compound **106** (89 mg, 69% yield):

¹H NMR (500 MHz, DMSO-*d*₆) δ 11.95 (s, 1H), 11.13 (s, 1H), 7.58 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.45 – 7.36 (m, 5H), 7.13 (d, *J* = 8.2 Hz, 2H), 6.93 (d, *J* = 8.2 Hz, 1H), 6.88 (d, *J* = 8.2 Hz, 2H), 6.51

(s, 1H), 4.79 (t, $J = 5.2$ Hz, 1H), 3.70 – 3.67 (m, 2H), 3.35 (s, 3H), 3.05 (bs, 2H), 2.85 (t, $J = 7.3$ Hz, 2H), 2.69 (bs, 1H), 2.53 – 2.47 (m, 5H), 2.19 (bs, 2H), 2.10 (s, 3H);


^{13}C NMR (125 MHz, DMSO- d_6) δ 170.4, 168.6, 166.4, 157.3, 141.9, 140.4, 139.8, 137.5, 129.9, 129.8, 128.3, 127.7, 125.6, 124.0, 123.6, 121.3, 119.5, 108.9, 97.5, 62.4, 59.2, 54.6, 52.4, 51.6,

5 45.8, 36.7;

HRMS (ESI-TOF) m/z calcd for $\text{C}_{33}\text{H}_{37}\text{N}_5\text{O}_5$ [$\text{M} + \text{H}^+$] 583.2795 found 584.2872.

(*Z*)-3-((4-Aminophenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylic acid (**107**)

10



To a solution of methyl (*Z*)-3-((4-aminophenyl)((4-(*N*-methyl-2-(4-methylpiperazin-1-yl)acetamido) phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (300 mg, 0.54 mmol) in
 15 MeOH/1,4-dioxane (1/1, 9 mL) was added aqueous 1N NaOH (3.0 mL) at 50 °C. This reaction mixture was stirred at 80 °C for 6h. The reaction solvent was evaporated under reduced pressure, and the residue was filtered by acetonitrile (5.0 mL) and diethyl ether (5.0 mL) to obtain the final compound **107** as a yellow solid (280 mg, 96% yield):


^1H NMR (500 MHz, DMSO- d_6) δ 11.84 (s, 1H), 10.65 (s, 1H), 7.57 (dd, $J = 7.9, 1.5$ Hz, 1H), 7.35
 20 (s, 1H), 7.10 (bs, 1H), 7.08 (d, $J = 8.4$ Hz, 3H), 6.73 (d, $J = 8.1$ Hz, 3H), 6.60 (d, $J = 8.2$ Hz, 2H), 5.66 (s, 2H), 3.06 (bs, 2H), 2.73 (bs, 2H), 2.24 (bs, 6H), 2.10 (s, 3H);

^{13}C NMR (125 MHz, DMSO- d_6) δ 171.3, 170.9, 168.7, 156.3, 150.6, 137.1, 132.5, 130.1, 127.5, 125.4, 123.0, 122.4, 120.5, 118.3, 113.7, 107.3, 101.3, 58.9, 54.6, 52.4, 45.8, 36.8;

HRMS (ESI-TOF) m/z calcd for $\text{C}_{30}\text{H}_{32}\text{N}_6\text{O}_4$ [$\text{M} + \text{H}^+$] 541.2558, found 541.2571.

25

(Z)-3-((3-Aminophenyl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylic acid (**108**)



5

To a solution of methyl (Z)-3-((3-aminophenyl)((4-(N-methyl-2-(4-methylpiperazin-1-yl)acetamido)phenyl)amino)methylene)-2-oxoindoline-5-carboxylate (23.8 mg, 0.14 mmol) in MeOH/1,4-dioxane (1/1, 3 mL) was added aqueous 1N NaOH (0.8 mL) at 50 °C. This reaction mixture was stirred at 80 °C for 6h. The reaction solvent was evaporated under reduced pressure, and the residue was filtered by acetonitrile (5 mL) and diethyl ether (5 mL) to obtain the final compound **108** as a yellow solid (18.6 mg, 80% yield):

10

HRMS (ESI-TOF) m/z calcd for $C_{31}H_{32}N_6O_6$ $[M + H^+]$ 540.2485 found 541.2549.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of skill in the art to which the disclosed invention belongs. Publications cited herein and the materials for which they are cited are specifically incorporated by reference.

15


Those skilled in the art will appreciate that numerous changes and modifications can be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is, therefore, intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

20

CLAIMS

We claim:

1. A compound of Formula I:



Formula I

wherein:


R¹ is hydrogen;

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino; and

R³ is selected from aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, comprising the formula:



Formula II

wherein:


R¹ is hydrogen; and

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino;


or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 or 2, wherein R² is ester.
4. The compound of any one of claims 1 to 3, wherein R³ is selected from phenyl, benzyl, pyridine, or furan.
5. The compound of any one of claims 1 to 3, wherein R³ is unsubstituted aryl.
6. The compound of any one of claims 1 to 3, wherein R³ is phenyl.
7. The compound of any one of claims 1 to 3, wherein R³ is substituted aryl.
8. The compound of any one of claims 1 to 3, wherein R³ is pyridine.
9. The compound of any one of claims 1 to 3, wherein R³ is furan.

10. The compound of claim 1, wherein the compound is




11. The compound of claim 1, wherein the compound is



12. A method for the treatment of a cancer, comprising:

administering an effective amount of a compound of Formula I to a host in need thereof:



Formula I

wherein:


R¹ is hydrogen;

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino; and

R³ is selected from aryl or heteroaryl;

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, wherein the compound comprises the formula:



Formula II

wherein:

R¹ is hydrogen; and

R² is selected from carboxylic acid, ester, amide, acyl, alkoxy, sulfonamide, alkylamino, aminoacyl, or amino;

or a pharmaceutically acceptable salt thereof.

14. The method of claim 12 or 13, wherein R² is ester.

15. The method of any one of claims 12 to 14, wherein R³ is selected from phenyl, benzyl, pyridine, or furan.

16. The method of any one of claims 12 to 14, wherein R³ is unsubstituted aryl.


17. The method of any one of claims 12 to 14, wherein R³ is phenyl.

18. The method of any one of claims 12 to 14, wherein R³ is substituted aryl.


19. The method of any one of claims 12 to 14, wherein R³ is pyridine.

20. The method of any one of claims 12 to 14, wherein R³ is furan.

21. The method of claim 12, wherein the compound is



22. The method of claim 12, wherein the compound is



23. The method of any one of claims 12 to 22, wherein the cancer is selected from triple negative breast cancer or glioblastoma multiforme.

24. The method of claim 23, wherein the cancer is triple negative breast cancer.
25. The method of claim 23, wherein the cancer is glioblastoma multiforme.
26. The method of any one of claims 12 to 25, wherein the compound is administered in combination with an additional chemotherapeutic agent.






FIG. 1




FIG. 2

3/8




FIG. 3





FIG. 4






FIG. 5




	Fractional Activity
Morrison Ki	
Best-fit values	
Vo	1
Et	=1
Ki	0.39
S	=40000
Km	=6000
Std. Error	
Vo	0.056
Ki	0.094




[MELK Inh] (nM)	Rate (nmol P/sec)	Mean	SEM
0.0	0.153200	0.002842	
0.5	0.123400	0.003158	
1.0	0.147500	0.005636	
2.5	0.095010	0.005656	
5.0	0.055740	0.003116	
10.0	0.031190	0.004180	
50.0	0.002999	0.001517	
100.0	0.006433	0.004358	
500.0	0.005170	0.007418	
1000.0	0.005649	0.001442	

FIG. 5 Cont.



Morrison Ki	Fractional Activity
Best-fit values	
Vo	1
Et	=0.96
Ki	0.68
S	=40000
Km	=6000
Std. Error	
Vo	0.023
Ki	0.074



[MELK Inh] (nM)	Rate (nmol P/sec)	
	Mean	SEM
0.0	0.1273000	0.0042850
0.5	0.1071000	0.0078400
1.0	0.1072000	0.0117800
2.5	0.0817600	0.0088870
5.0	0.0648800	0.0156500
10.0	0.0464500	0.0048950
50.0	0.0153200	0.0104800
100.0	0.0061000	0.0057190

FIG. 5 Cont.




FIG. 6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/20000

A. CLASSIFICATION OF SUBJECT MATTER
 IPC - A61K 31/404; C07D 403/06 (2018.01)
 CPC - A61K 31/404; C07D 403/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	(CENIK, BK et al.) 'BIBF 1120 (Nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer'; 06 June 2013, Molecular Cancer Therapeutics; Volume 12, Issue 6, pages 992-1001; abstract; page 993, first column, last paragraph; page 993, second column, first and second paragraphs; page 995, figure 1	1-2, 3/1-2, 10-13, 14/12-13, 21-22
Y	US 6,387,919 B1 (DAVIS, ST et al.) 14 May 2002; column 4, lines 15-25, 38-41, 59	1-2, 3/1-2, 10-13, 14/12-13, 21-22
A	US 2005/0009898 A1 (ROTH, GJ et al.) 13 January 2005; entire document	1-2, 3/1-2, 10-13, 14/12-13, 21-22

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 April 2018 (05.04.2018)

Date of mailing of the international search report

25 APR 2018

Name and mailing address of the ISA/

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
 P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300
 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US18/20668

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.: 4-9, 15-20, 23-26
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.